

An Independent Licensee of the Blue Cross and Blue Shield Association.

Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures

File Code: 10.01.VT204 Origination: 09/2016 Last Review: 12/01/2021 Next Review: 04/01/2022

Effective Date: 01/01/2022 (Adaptive Maintenance Only)

Description

The following outline current services and procedures considered to be investigational by Blue Cross Blue Shield of Vermont. If the following code is billed with the noted diagnosis codes, the service will deny as investigational.

Definition of Investigational

"Experimental of Investigational Services" means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating the condition, illness or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating the condition, illness or diagnosis for which their use is proposed.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL of the following criteria is considered to be "Investigational":

- 1. The technology must have final approval from the appropriate governmental regulatory bodies.
 - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration or any other federal governmental body with authority to regulate the use of the technology.
 - Any approval that is granted as an interim step in the U.S. Food and Drug Administration's orany other federal governmental body's regulatory process is not sufficient.
 - The indications for which the technology is approved need not be the same as those

Page 1 of **99**

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2022

which the Blue Cross and Blue Shield of Vermont (BCBSVT) Medical Policy Committee is evaluating.

- 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
 - The evidence should consist of well-designed and well-conducted investigations published in peer- reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
 - The evidence should demonstrate that the technology can measure or alter the physiological changes related to a disease, injury, illness, or condition. In addition, there should be evidence or a convincing argument based on established medical facts that such measurement or alteration affects health outcomes.
- 3. The technology must improve the net health outcome.
 - The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
- 4. The technology must be as beneficial as any established alternatives.
 - The technology should improve the net health outcome as much as, or more than, established alternatives.
- 5. The improvement must be attainable outside the investigational settings.
 - When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria#3 and #4.

In reviewing the above criteria, the BCBSVT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

Policy

The following is a list of current services and procedures grouped by discipline and/or function which are considered investigational and therefore not covered Attachment I

Policy Implementation/Update information

06/2020	Policy new Format
---------	-------------------

Page 2 of 99

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2022

40/2020	Coding Underes offertive 10/01/2020 Hedical Delicus Added and as 200711
10/2020	
	0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520,
	83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209,
	87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED
	INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9,
	K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89.
	Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle:
	Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U,
	0209U, 0211U, 0216U, 0217U, 0218U, 0219U, 0220U, 0225U, K1006,
	K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255.
01/2021	Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle:
	Changed effective date to 01/01/2021
	Removed Codes 38230, 83993, 90694
	Updated Codes 82172 & 84181 to Investigational for All diagnoses Updated
	Codes 64910, 64911, 64912, 64913 as Investigational with dx codes C61, N52.0-N52.9
	Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T,
	0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T,
	0635T, 0636T, 0637T,0638T, 0639T, 22869,22870 30468, 55880, 57465,
	81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775
	Deleted codes 0400T, 0401T
	Removed codes 38206, 38230, 38241 codes require PA
04/2021	Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle:
	Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019,
	K1020, S1091, 0242Ú, 0243Ú, 0244Ú, 0247Ú. Removed codes: K1010,
	K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835
05/2021	Coding Update effective 05/01/2021: Added codes 81518, 0045U,
	0153Ü.
07/2021	Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U,
	0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T,
	0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T,
	0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T,
	0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677,
	90758, C1761
08/2021	Coding Updates effective 08/01/2021: Added codes E1700, E1701,
33, 2021	E1702
09/2021	Coding update effective 09/01/2021: Removed code 53854
10/2021	Coding update effective 10/01/2021: Added Codes 0255U, 0258U,
10, 2021	0259U 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U,
	0280U, 0281U, 0282U, 0283U, 0284U, 0018M, Deleted code 0139U.
	Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780, K1023,
	K1024, K1025, K1026, Q4251, Q4252, Q4253
11/2021	Coding update effective 11/01/2021 (To Align Corporate
11/2021	Bioengineered Skin Medical Policy Table): Added codes C9354,
	C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111,
	Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125,
	Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143,
	Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166,
	Q4147, Q4147, Q4143, Q4152, Q4158, Q4161, Q4164, Q4163, Q4166, Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222.
	Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254, Q4255.
12/2024	Coding update effective 12/01/2021: Added code G9143
12/2021	3
12/2021	Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle):
	Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752,
	C9753, 95943, 0208U

Page **3** of **99**

I	Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454,
	61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U,
	0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0295U, 0296U,
	0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes
	CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T,
	0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T,
	0689T´, 0690T´, 0691T´, 0693T´, 0694T´, 0695T´, 0696T´, 0697T´, 0698T´,
	0700T´, 0701T´, 0702T´, 0703T´, 0704T´, 0705T´, 0706T´, 0707T´, 0708T´,
	0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS
	Codes: A2001, A2002, A2003, A2004, A2005, A2006, A2007, A2008,
	A2009, A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U,
	0032U, 0033U, 0173U, 0175U, 90677.

Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

Approved by BCBSVT Medical Directors

Date Approved

Joshua Plavin, MD, MPH, MBA Chief Medical Officer

Attachment I

CPT®/HCPCS Code	CPT®/HCPCS Code Description	Investigational Diagnoses
A2001	Innovamatrix ac, per square centimeter	All
A2002	Mirragen advanced wound matrix, per square centimeter	All
A2003	Bio-connekt wound matrix, per square centimeter	All
A2004	Xcellistem, per square centimeter	All
A2005	Microlyte matrix, per square centimeter	All
A2006	Novosorb synpath dermal matrix, per square centimeter	All
A2007	Restrata, per square centimeter	All
A2008	Theragenesis, per square centimeter	All
A2009	Symphony, per square centimeter	All
A2010	Apis, per square centimeter	All
A4563	Rectal Control System for Vaginal Insertion, For Long Term Use, Includes Pump And All Supplies And Accessories, Any Type Each	All

Page 4 of 99

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2022

A4575	Topical Hyperbaric Oxygen	All
	Chamber, Disposable	
A4641	Radiopharmaceuti-Cal, Diagnostic,	R92.0-R92.8
	Not Otherwise Classified	Z12.31-Z12.39
A4642	Indium In-111 Satumomab	R92.0-R92.8 Z12.31-Z12.39
	Pendetide, Diagnostic, Per Study	
	Dose, Up To 6 Millicuries	
A4648	Tissue Marker, Implantable, Any	C34.00- C34.92
	Type, Each	C85.28 R59.0 R59.1 R91.8
A9500	Technetium Tc-99M Sestamibi,	R92.0-R92.8 Z12.31-Z12.39
	Diagnostic, Per Study Dose	
A9502	Technetium Tc-99M Tetrofosmin,	R92.0-R92.8 Z12.31-Z12.39
A7302	Diagnostic, Per Study Dose	10/2.0 10/2.0 212.31 212.37
A9507	Indium In-111 Capromab	All
A7307	Pendetide, Diagnostic, Per Study	Att
	Dose, Up To 10 Millicuries	
A9520	Technetium Tc-99M Tilmanocept,	R92.0-R92.8
A7320	Diagnostic, Up To 0.5 Millicuries	Z12.31-Z12.39
A9541	Technetium Tc-99M Sulfur Colloid,	R92.0-R92.8 Z12.31-Z12.39
A9341	·	K92.U-K92.0 Z12.31-Z12.39
	Diagnostic, Per Study Dose, Up To 20 Millicuries	
A9568		D03 0 D03 9
A9368	Technetium Tc-99M Arcitumomab,	R92.0-R92.8
	Diagnostic, Per Study Dose, Up To	Z12.31-Z12.39
40570	45 Millicurie	D00 0 D00 0 740 04 740 00
A9572	Indium In-111 Pentetreotide,	R92.0-R92.8 Z12.31-Z12.39
	Diagnostic, Per Study Dose, Up To 6	
1000	Millicuries	150 4 150 0
A9582	lodine I-123 iobenguane, diagnostic,	150.1-150.9
	per study dose, up to 15 mCi	
A9584	Iodine I-123 Ioflupane, Diagnostic,	G20
	Per Study Dose, Up To 5 Millicuries	G21.0-G21.9 G31.83
A9586	Florbetapir F18, Diagnostic, Per	All
	Study Dose, Up To 10 Millicuries	
A9593	Gallium ga-68 psma-11, diagnostic,	All
	(ucsf), 1 millicurie	
A9594	Gallium ga-68 psma-11, diagnostic,	All
	(ucla), 1 millicurie	
A9599	Radiopharmaceutical, Diagnostic,	All
	For Beta- Amyloid Positron	
	Emission Tomography (Pet)	
	Imaging, Per Study Dose, Not	
	Otherwise Specified	
C1734	Orthopedic/Device/Drug Matrix For	All
	Opposing Bone-To-Bone Or Soft	
	Tissue-To Bone (Implantable)	
C1761	Catheter, transluminal	All
3.751	intravascular lithotripsy, coronary	
L	marascatai ticiioti ipsy, coi olidi y	1

Page **5** of **99**

C1821	Interspinous Process Distraction Device (Implantable).	All
C1823	Generator, Neurostimulator	All
0.020	(Implantable), Non- Rechargeable,	····
	With Transvenous Sensing And	
	Stimulation Leads	
C1831	Personalized, anterior and lateral	All
	interbody cage (implantable)	
C1832	Autograft suspension, including cell	All
	processing and application, and all	
	system components	
C1833	Monitor, cardiac, including	All
	intracardiac lead and all system	
	components (implantable)	
C1841	Retinal Prosthesis, Includes All Internal	All
COFOC	And External Components	A11
C2596	Probe, Image-Guided, Robotic,	All
C2614	Waterjet Ablation	All
C2614	Probe, Percutaneous Lumbar	All
C8937	Discectomy Computer-Aided Detection, Including	All
C0937	Computer Algorithm Analysis Of Breast	Att
	Mri Image Data For Lesion	
	Detection/Characterization,	
	Pharmacokinetic Analysis, With	
	Further Physician Review For	
	Interpretation (List Separately In	
	Addition To Code For Primary	
	Procedure)	
C9122	Mometasone furoate sinus implant,	All
	10 mcg (Sinuva)	
C9354	Acellular pericardial tissue matrix	All
	of nonhuman origin (Veritas), per	
	sq cm	
C9356	Tendon, porous matrix of cross-	All
	linked collagen and	
C9358		All
C7330		All
	• · · · · · · · · · · · · · · · · · · ·	
C9360		All
	· · · · · · · · · · · · · · · · · · ·	
	3 ,	
	Matrix), per 0.5 sq cm	
C9358	glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	All

Page **6** of **99**

C9363	Clain substitute (Integra Meshed	All
C9303	Skin substitute (Integra Meshed	All
	Bilayer Wound Matrix), per sq cm	
C9364	Porcine implant, Permacol, per sq	All
	cm	
C9750	Insertion Or Removal And	All
	Replacement Of Intracardiac	
	Ischemia Monitoring System	
	Including Imaging, Supervision And	
	Interpretation, And Peri-Operative	
	Interrogation And Programming;	
	Complete System (Includes Device	
	And Electrode)	
C9751	,	All
C9/51	Bronchoscopy, Rigid Or Flexible,	All
	Transbronchial Ablation Of	
	Lesion(S) By Microwave Energy,	
	Including Fluoroscopic Guidance,	
	When Performed, With Computed	
	Tomography Acquisition(S) And 3-D	
	Rendering, Computer- Assisted,	
	Image-Guided Navigation, And	
	Endobronchial Ultrasound (Ebus)	
	Guided Transtracheal And/Or	
	Transbronchial Sampling (E.G.,	
	Aspiration[S]/Biopsy[les]) And All	
	Mediastinal And/Or Hilar Lymph	
	Node Stations Or Structures And	
	Therapeutic Intervention(S)	
C9758	Blinded Procedure for Nyha Class	All
C7750	lii/ly Heart Failure; Transcatheter	All
	Implantation Of Interatrial Shunt Or	
	Placebo Control, Including Right	
	Heart Catheterization, Trans-	
	•	
	Esophageal Echocardiography	
	(Tee)/Intracardiac	
	Echocardiography (Ice), And All	
	Imaging With Or Without Guidance	
	(E.G., Ultrasound, Fluoroscopy),	
	Performed In An Approved	
	Investigational Device Exemption	
	(Ide) Study	
C9759	Transcatheter intraoperative blood	All
	vessel microinfusion(s) (e.g.,	
	intraluminal, vascular wall and/or	
	perivascular) therapy, any vessel,	
	including radiological supervision	
	and interpretation, when	
	performed	
	periornica	

Page **7** of **99**

C9760	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	All
C9762	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	All
C9763	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	All
C9764	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	All
C9765	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	All
C9766	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	All
C9767	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular	All

Page **8** of **99**

	lithotripsy and transluminal stent	
	placement(s), and atherectomy,	
	1.	
	includes angioplasty within the	
60774	same vessel(s), when performed	All
C9771	Nasal/sinus endoscopy,	All
	cryoablation nasal tissue(s) and/or	
	nerve(s), unilateral or bilateral	
C9772	Revascularization, endovascular,	All
	open or percutaneous,	
	tibial/peroneal artery(ies), with	
	intravascular lithotripsy, includes	
	angioplasty within the same vessel	
	(s), when performed	
C9773	Revascularization, endovascular,	All
	open or percutaneous,	7
	tibial/peroneal artery(ies); with	
	intravascular lithotripsy, and	
	transluminal stent placement(s),	
	includes angioplasty within the	
C9774	same vessel(s), when performed	All
C9774	Revascularization, endovascular,	Att
	open or percutaneous,	
	tibial/peroneal artery(ies); with	
	intravascular lithotripsy and	
	atherectomy, includes angioplasty	
	within the same vessel (s), when	
	performed	
C9775	Revascularization, endovascular,	All
	open or percutaneous,	
	tibial/peroneal artery(ies); with	
	intravascular lithotripsy and	
	transluminal stent placement(s),	
	and atherectomy, includes	
	angioplasty within the same vessel	
	(s), when performed	
C9776	Intraoperative near-infrared	All
	fluorescence imaging of major	
	extra-hepatic bile duct(s) (e.g.,	
	cystic duct, common bile duct and	
	common hepatic duct) with	
	intravenous administration of	
	indocyanine green (icg) (list	
	separately in addition to code for	
	primary procedure)	
C9777	Esophageal mucosal integrity	All
	testing by electrical impedance,	
	transoral (list separately in	
	Liansoral (list separately in	1

Page **9** of **99**

	·	
	addition to code for primary procedure)	
C9780	Insertion of central venous	All
	catheter through central venous	
	occlusion via inferior and superior	
	approaches (e.g., inside-out	
	technique), including imaging	
	guidance	
E0218	Water Circulating Cold Pad With	All
EUZ 16	Pump	All
E0236	Pump For Water Circulating Pad	All
E0740	Incontinence Treatment System;	F98.0
E0740		F98.1 N39.3
	Pelvic Floor Stimulator, Monitor,	N39.41-N39.498 R15.9
F07.40	Sensor And/Or Trainer	
E0748	Osteogenesis Stimulator, Electrical,	M43.22
F07.40	Non- Invasive, Spinal Applications	
E0749	Osteogenesis Stimulator, (Surgically	M43.22
	Implanted)	
E0761	Non-Thermal Pulsed High	E08.621 E08.622 E09.621 E09.622
	Frequency Radiowaves, High Peak	E10.621 E10.622 E11.621 E11.622
	Power Electromagnetic Energy	E13.621 E13.622 I83.001-I83.029
	Treatment Device	I83.201-I83.229 L00-L08.9 L89.00-
		L89.95 L97.10-L97.929 L98.41-
		L98.499 L99
E0769	Electrical Stimulation Or	E08.621
	Electromagnetic Wound Treatment	E08.622 E09.621 E09.622 E10.621
	Device, Not Otherwise	E10.622 E11.621 E11.622 E13.621
		E13.622 I83.001-I83.029 I83.201-
		183.229 L00-L08.9 L89.00-L89.95
		L97.10-L97.929 L98.41-L98.499 L99
E1700	Jaw motion rehabilitation system	All
E1701	Replacement cushions for jaw motion	All
	rehabilitation system, package of 6	
E1702	Replacement measuring scales for jaw	All
	motion rehabilitation system, package	
	of 200	
G0166	External Counterpulsation, Per	Z13.6 Z82.41 Z82.49
	Treatment Session	
G0255	Current Perception	All
	Threshold/Sensory Nerve	
	Conduction Test (Snct), per limb,	
	any nerve	
G0259	Injection Procedure for Sacroiliac	M46.1 M47.898 M47.899 M48.08
33237	Joint; Arthrography	M53.2X8 M53.3 M54.18
	στ, τ σει αριίς	M54.30-M54.32 M54.40-M54.42
		M54.5
		M54.6 S33.2XXX S33.6XXX
		M97.0 JJJ,E//// JJJ,U////

Page 10 of 99 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

G0276	Blinded Procedure For Lumbar Stenosis, Percutaneous Image- Guided Lumbar Decompression (Pild) Or Placebo-Control, Performed In An Approved Coverage With Evidence Development (Ced) Clinical Trial Electrical Stimulation, (Unattended), To One Or More Areas, For Chronic Stage Iii And Stage Iv Press Ure Ulcers, Arterial Ulcers, Diabetic Ulcers, And Venous	E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 I83.001-I83.029 I83.201- I83.229 L00-L08.9 L89.00-L89.95
G0282	Stasis Ulcers Not Demonstrating Measurable Electrical Stimulation, (Unattended), To One Or More Areas, For Wound Care Other Than Described In G0 281	L97.10-L97.929 L98.41-L98.499 L99 E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 I83.001-I83.029 I83.201-I83.229 L00-L08.9 L89.00- L89.95 L97.10-L97.929 L98.41- L98.499 L99
G0295	Electromagnetic Therapy, To One Or More Areas, For Wound Care Other Than Described In G0329 Or For Other Uses	E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 I83.001-I83.029 I83.201- I83.229 L00-L08.9 L89.00-L89.95 L97.10-L97.929 L98.41-L98.499 L99
G0327	Colorectal cancer screening; blood- based biomarker	All
G0329	Electromagnetic Therapy, To One Or More Areas For Chronic Stage Iii And Stage	E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 I83.001-I83.029 I83.201-I83.229 L00-L08.9 L89.00- L89.95 L97.10-L97.929 L98.41- L98.499 L99
G0465	Autologous platelet rich plasma (prp) for diabetic chronic wounds/ulcers, using an fdacleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)	All
G2000	Blinded Administration Of Convulsive Therapy Procedure, Either Electroconvulsive Therapy (Ect, Current Covered Gold	All

Page 11 of 99

	Standard) Or Magnetic Seizure	
	Therapy (Mst, Non-Covered	
	Experimental Therapy), Performed	
	In An Approved Ide-Based Clinical	
	Trial, Per Treatment Session	
G2170	Percutaneous arteriovenous fistula	All
	creation (AVF), direct, any site, by	
	tissue approximation using thermal	
	resistance energy, and secondary	
	procedures to redirect blood flow	
	•	
	(e.g., transluminal balloon	
	angioplasty, coil embolization)	
	when performed, and includes all	
	imaging and radiologic guidance,	
	supervision and interpretation,	
	when performed	
G2171	Percutaneous arteriovenous fistula	All
	creation (AVF), direct, any site,	
	using magnetic-guided arterial and	
	venous catheters and	
	radiofrequency energy, including	
	flow- directing procedures (e.g.,	
	vascular coil embolization with	
	radiologic supervision and	
	interpretation, when performed)	
	· · · · · · · · · · · · · · · · · · ·	
	and fistulogram(s), angiography,	
	veinography, and/or ultrasound,	
	with radiologic supervision and	
	interpretation, when performed	
G9143	Warfarin responsiveness testing	All
	by genetic technique using any	
	method, any number of	
	specimen(s)	
G9147	Outpatient Intravenous Insulin	E08.8-E13.9
	Treatment (Oivit) Either Pulsatile	
	Or Continuous, By Any Means,	
	Guided By The Results Of	
	Measurements For: Respiratory	
	Quotient; And/Or, Urine Urea	
J3490	Nitrogen (Uun). Unclassified drugs	Ago 12 + years of ago
J3470	onclassified drugs	Age 13 + years of age -
		Investigational if any of the one
		diagnosis codes is present on
		submitted claim: (F31.4, F31.5,
		F31.60, F31.61, F31.62, F31.63,
		F31.64, F31.70, F31.71, F31.72,
		F31.73, F31.74, F31.75, F31.76,

Page **12** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

		F34 77 F34 70 F34 04 F34 00
		F31.77, F31.78, F31.81, F31.89,
		F31.9, F32.0, F32.1,F32.3,
		F32.4, F32.5, F32.8, F32.9,
		F33.0, F33.1, F33.3, F33.40,
		F33.41, F33.42, F34.0, F34.1,
		F34.81, F34.89, F34.9, F39,
		G89.0, G89.11, G89.12, G89.18,
		G89.21, G89.22, G89.28,
		G89.29, G89.3, G89.4)
J9035	Injection, Bevacizumab, 10 Mg.	C25.0-C25.9
K1001	Electronic Positional Obstructive	All
KIOOI		Att
	Sleep Apnea Treatment, With	
	Sensor, Includes All Components	
1//000	And Accessories, Any Type	
K1002	Cranial Electrotherapy Stimulation	All
	(Ces) System, Includes All Supplies	
	And Accessories, Any Type	
K1004	Low Frequency Ultrasonic	All
	Diathermy Treatment Device For	
	Home Use, Includes All Components	
	And Accessories	
K1006	Suction pump, home model,	All
	portable or stationary, electric,	
	any type, for use with external	
	urine management system	
K1007	Bilateral hip, knee, ankle, foot	All
K1007		Att
	device, powered, includes pelvic	
	component, single or double	
	upright(s), knee joints any type,	
	with or without ankle joints any	
	type, includes all components and	
	accessories, motors,	
	microprocessors, sensors	
K1016	Transcutaneous electrical nerve	All
	stimulator for electrical stimulation	
	of the trigeminal nerve	
K1017	Monthly supplies for use of device	All
1017	coded at k1016	
K1018	External upper limb tremor	All
KIOIO	stimulator of the peripheral nerves	700
	of the wrist	
V1010		All
K1019	Monthly supplies for use of device	All
1/4000	coded at K1018	
K1020	Non-invasive vagus nerve	All
	stimulator	
K1023	Distal transcutaneous electrical	All
	nerve stimulator, stimulates	
l	,	

Page 13 of 99 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

	peripheral nerves of the upper arm	
K1024	Non-pneumatic compression	All
11.02	controller with sequential	,
	calibrated gradient pressure	
K1025	Non-pneumatic sequential	All
KIOZS	compression garment, full arm	Att
K1026	Mechanical allergen particle	All
111020	barrier/inhalation filter, cream,	
	nasal, topical	
L8603	Collagen Implant Material, Such As	N39.3 R15.0-R15.9
	Contigen	
L8605	Injectable Bulking Agent,	N39.3
	Dextranomer/Hyalu-	R15.0-R15.9
	Ronic Acid Copolymer Implant, Anal	
	Canal, 1 Ml, Includes Shipping and	
	Necessary Supplies	
L8606	Synthetic Bulking Agents, Such As	N39.3
	Carbon-Coated Beads Or	R15.0-R15.9
	Copolymers (Durasphere Or Uryx).	
L8608	Miscellaneous External Component,	All
	Supply Or Accessory For Use With	
	The Argus Ii Retinal Prosthesis	
	System	
L8680	Implantable Neurostimulator	F32.0-F33.9 G43.0-G44.89
	Electrode, Each	H93.1-H93.19 H93.A1-H93.A9
		M79.7
		150-150.9 S06-S06.9X9
L8681	Patient programmer (external) for	F32.0-F33.9 G43.0-G44.89
	use with implantable	H93.1-H93.19 H93.A1-H93.A9
	programmable neurostimulator	M79.7
	pulse generator, replacement only	150-150.9 S06-S06.9X9
L8682	Implantable neurostimulator	F32.0-F33.9 G43.0-G44.89
	radiofrequency receiver	H93.1-H93.19 H93.A1-H93.A9
		M79.7
L8683	Padiofraguancy transmitter	150-150.9 S06-S06.9X9 F32.0-F33.9
LUUUS	Radiofrequency transmitter (external) for use with implantable	G43.0-G44.89 H93.1-H93.19
	neurostimulator radiofrequency	H93.A1-H93.A9 M79.7
	receiver	150-150.9 S06-S06.9X9
L8684	Radiofrequency transmitter	F32.0-F33.9 G43.0-G44.89
LUUU4	(external) for use with implantable	H93.1-H93.19 H93.A1-H93.A9
	sacral root neurostimulator	M79.7
	receiver for bowel and bladder	150-150.9 S06-S06.9X9
	management, replacement	150 150.7 500 500.7
L8685	Implantable neurostimulator pulse	F32.0-F33.9
	generator, single array,	G43.0-G44.89 H93.1-H93.19
	rechargeable, includes extension	H93.A1-H93.A9 M79.7
	rechargeable, metades extension	11731711 1173177 1111 711

Page **14** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

		150-150.9 S06-S06.9X9
L8686	Implantable neurostimulator pulse	F32.0-F33.9 G43.0-G44.89
	generator, single array,	H93.1-H93.19 H93.A1-H93.A9
	nonrechargeable, includes	M79.7
	extension	150-150.9 S06-S06.9X9
L8687	Implantable neurostimulator pulse	F32.0-F33.9 G43.0-G44.89
	generator, dual array,	H93.1-H93.19 H93.A1-H93.A9
	rechargeable, includes extension	M79.7
	rechargeaste, metades extension	150-150.9 S06-S06.9X9
L8688	Implantable neurostimulator pulse	F32.0-F33.9 G43.0-G44.89
	generator, dual array,	H93.1-H93.19 H93.A1-H93.A9
	nonrechargeable, includes	M79.7
	extension	150-150.9 S06-S06.9X9
L8689	External recharging system for	F32.0-F33.9 G43.0-G44.89 H93.1-
	battery (internal) for use with	H93.19 H93.A1-H93.A9 M79.7
	implantable neurostimulator,	150-150.9 S06-S06.9X9
	replacement only	
Q4103	Oasis burn matrix, per sq cm	All
Q4104	Integra bilayer matrix wound	All
	dressing (BMWD), per sq cm	
Q4110	PriMatrix, per sq cm	All
Q4111	GammaGraft, per sq cm	All
Q4112	Cymetra, injectable, 1 cc	All
Q4113	GRAFTJACKET XPRESS, injectable,	All
0.1115	1 cc	
Q4115	AlloSkin, per sq cm	All
Q4117	HYALOMATRIX, per sq cm	All
Q4118	MatriStem micromatrix, 1 mg	All
Q4121	TheraSkin, per sq cm	All
Q4123	AlloSkin RT, per sq cm	All
Q4124	OASIS ultra tri-layer wound matrix,	All
04425	per sq cm	All
Q4125	ArthroFlex, per sq cm	All
Q4126	MemoDerm, DermaSpan,	All
Q4127	TranZgraft or InteguPly, per sq cm	All
Q4127 Q4130	Talymed, per sq cm Strattice TM, per sq cm	All
Q4130 Q4134	HMatrix, per sq cm	All
Q4134 Q4135	Mediskin, per sq cm	All
Q4133 Q4136	E-Z Derm, per sq cm	All
Q4141	AlloSkin AC, per sq cm	All
Q4142	XCM biologic tissue matrix, per sq	All
21172	cm	7.00
Q4143	Repriza, per sq cm	All
Q4146	Tensix, per sq cm	All
Q4147	Architect, Architect PX, or	All
• • • • • • • • • • • • • • • • • • •	Architect FX, extracellular matrix,	
	per sq cm	
	per 3q cm	

Page **15** of **99**

Q4149	Excellagen, 0.1 cc	All
Q4152	DermaPure, per sq cm	All
Q4158	Kerecis Omega3, per sq cm	All
Q4161	bio-ConneKt wound matrix, per sq	All
	cm	
Q4164	Helicoll, per sq cm	All
Q4165	Keramatrix or Kerasorb, per sq cm	All
Q4166	Cytal, per sq cm	All
Q4167	Truskin, per sq cm	All
Q4179	FlowerDerm, per sq cm	All
Q4182	Transcyte, per sq cm	All
Q4193	Coll-e-Derm, per sq cm	All
Q4196	PuraPly AM, per sq cm	All
Q4199	Cygnus matrix, per square centimeter	All
Q4200	SkinTE, per sq cm	All
Q4202	Keroxx (2.5 g/cc), 1 cc	All
Q4203	Derma-Gide, per sq cm	All
Q4222	ProgenaMatrix, per sq cm	All
Q4251	Vim, per square centimeter	All
Q4252	Vendaje, per square centimeter	All
Q4253	Zenith amniotic membrane, per	All
	square centimeter.	
Q9982	Flutemetamol F18, Diagnostic, Per	All
	Study Dose, Up To 5 Millicuries	
Q9983	Florbetaben F18, Diagnostic, Per	All
	Study Dose, Up To 8.1 Millicuries	
S1090	Mometasone Furoate Sinus Implant,	All
	370 Micrograms	
S1091	Stent, non-coronary, temporary,	All
	with delivery system (propel)	
S2080	Laser-Assisted Uvulopalato-Plasty	G47.09-G47.39
32000	(Laup)	
S2117	Arthroereisis, Subtalar	All
S2230	Implantation Of Magnetic	All
	Component Of Semi-Implantable	
	Hearing Device On Ossicles In	
	Middle Ear	
S2348	Decompression Procedure,	All
323 10	Percutaneous, Of Nucleus Pulposus	Att
	Of Intervertebral Disc, Using	
	Radiofrequency Energy, Single Or	
	Multiple Levels, Lumbar.	
S3722	Dose Optimization By Area-Under-	C18.0-C18.9
	The-Curve (Auc) Analysis For	C19
	Infusional 5-Fluorouracil (5- Fu)	
S3852	Dna Analysis For Apoe Epsilon 4	GO3
33032	Allele For Susceptibility To	G30.0-G30.9 G31.1
	Allzheimer's Disease	R41.0
	Atzneimer 5 Disease	1.0

Page **16** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

		R41.81 Z13.858 Z31.430 Z31.440
		Z82.0
S8080	Scintimammography	R92.0-R92.8
	(Radioimmunoscintigraphy	Z12.31-Z12.39
	Of The Breast), Unilateral,	
	Including Supply Of	
	Radiopharmaceuti-Cal	
S8930	Electrical Stimulation Of Auricular	All
	Acupuncture Points; Each 15	
	Minutes Of Personal One-On- One	
	Contact With The Patient.	
S8960	Electrical Stimulation Of Auricular	All
	Acupuncture Points; Each 15	
	Minutes Of Personal One-On- One	
	Contact With The Patient	
S9090	Vertebral Axial Decompression, Per	All
	Session	
V2799	Vision Item Or Service,	All
	Miscellaneous	
V5095	Semi-Implantable Middle Ear	All
	Hearing Prosthesis	
0003U	Oncology (Ovarian) Biochemica	D27.0-D27.9 D39.10-D39.12
	Assays Of Five Proteins	D49.511 D49.512 D49.519
	(Apolipoprotein A-1 Ca 125 li,	R19.01-R19.02
	Follicle Stimulating Hormone,	
	Human Epididymis Protein 4,	
	Transferrin), Utilizing Serum,	
	Algorithm Reported As A Likelihood	
	Score.	
0004M	Scoliosis, DNA Analysis Of 53 Single	All
	Nucleotide Polymorphisms (Snps),	
	Using Saliva, Prognostic Algorithm	
	Reported As A Risk Score	
0011M	Oncology, Prostate Cancer, mRNA	All
	Expression Assay Of 12 Genes (10	
	Content And 2 Housekeeping), Rt-	
	Pcr Test Utilizing Blood Plasma And	
	Urine, Algorithms To Predict High-	
	Grade Prostate Cancer Risk	
0014M	Liver disease, analysis of 3	All
··	biomarkers (hyaluronic acid [HA],	
	procollagen III amino terminal	
	peptide [PIIINP], tissue inhibitor of	
	metalloproteinase 1 [TIMP-1]),	
	using immunoassays, utilizing	
	serum, prognostic algorithm	
	reported as a risk score and risk of	

Page 17 of 99

	liver fibrosis and liver-related	
	clinical events within 5 years	
0016M	Oncology (bladder), mRNA,	All
	microarray gene expression	
	profiling of 209 genes, utilizing	
	formalinfixed paraffin-embedded	
	tissue, algorithm reported as	
	molecular subtype (luminal,	
	luminal infiltrated, basal, basal	
	claudin-low, neuroendocrine-like)	
0018M	Transplantation medicine (allograft	All
	rejection, renal), measurement of	
	donor and third-party-induced	
	CD154+T-cytotoxic memory cells,	
	utilizing whole peripheral blood,	
	algorithm reported as a rejection	
	risk score	
0024U	Glycosylated acute phase proteins	All
	(GlycA), nuclear magnetic	
	resonance spectroscopy,	
	quantitative	
0025U	Tenofovir, by liquid	All
33233	chromatography with tandem mass	
	spectrometry (LC-MS/MS), urine,	
	quantitative	
0026U	Oncology (thyroid), DNA and mRNA of	All
	112 genes, next-generation	
	sequencing, fine needle aspirate of	
	thyroid nodule, algorithmic analysis	
	reported as a categorical result	
	("Positive, high probability of	
	malignancy" or "Negative, low	
	probability of malignancy")	
0029U	Drug metabolism (adverse drug	All
00270	reactions and drug response), targeted	
	sequence analysis (ie, CYP1A2,	
	CYP2C19, CYP2C9, CYP2D6, CYP3A4,	
	CYP3A5, CYP4F2, SLCO1B1, VKORC1	
	and rs12777823)	
0031U	CYP1A2 (cytochrome P450 family 1,	All
333.0	subfamily A, member 2) (eg, drug	7.00
	metabolism) gene analysis, common	
	variants (ie, *1F, *1K, *6, *7)	
0034U	TPMT (thiopurine S-	All
00370	methyltransferase), NUDT15 (nudix	All
	hydroxylase 15)(eg, thiopurine	
	, , ,	
	metabolism) gene analysis, common	

Page **18** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

	variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)	
0035U	Neurology (Prion Disease),	All
	Cerebrospinal Fluid, Detection Of	
	Prion Protein By Quaking-Induced	
	Conformational Conversion,	
	Qualitative	
0037U	Targeted Genomic Sequence	All
	Analysis, Solid Organ Neoplasm,	,
	Dna Analysis Of 324 Genes,	
	Interrogation For Sequence	
	Variants, Gene Copy Number	
	Amplifications, Gene	
	Rearrangements, Microsatellite	
	Instability And Tumor Mutational	
	Burden	
0038U	Vitamin D, 25 Hydroxy D2 And D3,	All
00380		All
	By Lc-Ms/Ms, Serum Microsample,	
002011	Quantitative	All
0039U	Deoxyribonucleic Acid (Dna)	All
	Antibody, Double Stranded, High	
00.4411	Avidity	
0041U	Borrelia Burgdorferi, Antibody	All
	Detection Of 5 Recombinant	
	Protein Groups, By Immunoblot,	
	Igm	
0042U	Borrelia Burgdorferi, Antibody	All
	Detection Of 12 Recombinant	
	Protein Groups, By Immunoblot, Igg	
0043U	Tick-Borne Relapsing Fever Borrelia	All
	Group, Antibody Detection To 4	
	Recombinant Protein Groups, By	
	Immunoblot, Igm	
0044U	Tick-Borne Relapsing Fever Borrelia	All
	Group, Antibody Detection To 4	
	Recombinant Protein Groups, By	
	Immunoblot, Igg	
0045U	Oncology (breast ductal carcinoma	All
	in situ), mRNA, gene expression	
	profiling by real-time RT-PCR	
	of 12 genes (7 content and 5	
	housekeeping), utilizing formalin-	
	fixed paraffin-embedded tissue,	
	algorithm reported as recurrence	
	score	
0047U	Oncology (Prostate), Mrna, Gene	All
	Expression Profiling By Real-Time	
L		1

Page 19 of 99

	Rt-Pcr Of 17 Genes (12 Content And 5 Housekeeping), Utilizing Formalin-Fixed Paraffin-Embedded Tissue, Algorithm Reported As A Risk Score	
0048U	Oncology (Solid Organ Neoplasia), Dna, Targeted Sequencing Of Protein-Coding Exons Of 468 Cancer-Associated Genes, Including Interrogation For Somatic Mutations And Microsatellite Instability, Matched With Normal Specimens, Utilizing Formalin-Fixed Paraffin- Embedded Tumor Tissue, Report Of Clinically Significant Mutation(S)	
0050U	Targeted Genomic Sequence Analysis Panel, Acute Myelogenous Leukemia, Dna Analysis, 194 Genes Interrogation For Sequence Variants, Copy Number Variants Or Rearrangements	All
0051U	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	All
0052U	Prescription Drug Monitoring, Evaluation Of Drugs Present By Lc- Ms/Ms, Urine, 31 Drug Panel, Reported As Quantitative Results, Detected Or Not Detected, Per Date Of Service	All
0053U	Oncology (Prostate Cancer), Fish Analysis Of 4 Genes (Asap1, Hdac9, Chd1 And Pten), Needle Biopsy Specimen, Algorithm Reported As Probability Of Higher Tumor Grade	All
0054U	Prescription Drug Monitoring, 14 Or More Classes Of Drugs And Substances, Definitive Tandem Mass Spectrometry With Chromatography, Capillary Blood, Quantitative Report With Therapeutic And Toxic Ranges, Including Steady-State Range For	All

Page **20** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

	The December of December 1	
	The Prescribed Dose When	
OOFFII	Detected, Per Date Of Service	All
0055U	Cardiology (Heart Transplant), Cell-	All
	Free Dna, Pcr Assay Of 96 Dna	
	Target Sequences (94 Single	
	Nucleotide Polymorphism Targets	
0058U	And Two Control Targets), Plasma	All
00380	Oncology (Merkel Cell Carcinoma),	All
	Detection Of Antibodies To The	
	Merkel Cell Polyoma Virus	
	Oncoprotein (Small T Antigen),	
0059U	Serum, Quantitative	All
00390	Oncology (Merkel Cell Carcinoma),	All
	Detection Of Antibodies To The	
	Merkel Cell Polyoma Virus Capsid	
	Protein (Vp1), Serum, Reported As Positive Or Negative	
0060U	Twin Zygosity, Genomic Targeted	All
00000	Sequence Analysis Of Chromosome	Att
	2, Using Circulating Cell-Free Fetal	
	Dna In Maternal Blood	
0061U	Transcutaneous Measurement Of	All
00010	Five Biomarkers (Tissue	Att
	Oxygenation [Sto2], Oxyhemoglobin	
	[Cthbo2], Deoxyhemoglobin	
	[Cthbr], Papillary And Reticular	
	Dermal Hemoglobin Concentrations	
	[Cthb1 And Cthb2]), Using Spatial	
	Frequency Domain Imaging (Sfdi)	
	And Multi-Spectral Analysis	
0062U	Autoimmune (Systemic Lupus	All
00020	Erythematosus), Igg And Igm Analysis	Att
	Of 80 Biomarkers, Utilizing Serum,	
	Algorithm Reported With A Risk Score	
0067U	Oncology (Breast),	All
	Immunohistochemistry, Protein	
	Expression Profiling Of 4 Biomarkers	
	(Matrix Metalloproteinase-1 [Mmp-1],	
	Carcinoembryonic Antigen-Related	
	Cell Adhesion Molecule 6 [Ceacam6],	
	Hyaluronoglucosaminidase [Hyal1],	
	Highly Expressed In Cancer Protein	
	[Hec1]), Formalin- Fixed Paraffin-	
	Embedded Precancerous Breast	
	Tissue, Algorithm Reported As	
	Carcinoma Risk Score	
L		<u> </u>

Page **21** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0069U	Oncology (Colorectal), Microrna, Rt-Pcr Expression Profiling Of Mir- 31-3P, Formalin- Fixed Paraffin- Embedded Tissue, Algorithm Reported As An Expression Score	All
0075T	Transcatheter Placement Of Extracranial Vertebral Artery Stent(S), Including Radiologic Supervision And Interpretation, Open Or Percutaneous; Initial Vessel	All
0076T	Each Additional Vessel (Lis Separately In Addition To Code For Primary Procedure).	All
0078U	Pain Management (Opioid-Use Disorder) Genotyping Panel, 16 Common Variants (Ie, Abcb1, Comt, Dat1, Dbh, Dor, Drd1, Drd2, Drd4, Gaba, Gal, Htr2A, Httlpr, Mthfr, Muor, Oprk1, Oprm1), Buccal Swab Or Other Germline Tissue Sample, Algorithm Reported As Positive Or Negative Risk Of Opioid-Use Disorder	All
0080U	Oncology (Lung), Mass Spectrometric Analysis Of Galectin-3-Binding Protein And Scavenger Receptor Cysteine- Rich Type 1 Protein M130, With Five Clinical Risk Factors (Age, Smoking Status, Nodule Diameter, Nodule- Spiculation Status And Nodule Location), Utilizing Plasma, Algorithm Reported As A Categorical Probability Of Malignancy	All
0082U	Drug Test(S), Definitive, 90 Or More Drugs Or Substances, Definitive Chromatography With Mass Spectrometry, And Presumptive, Any Number Of Drug Classes, By Instrument Chemistry Analyzer (Utilizing Immunoassay), Urine, Report Of Presence Or Absence Of Each Drug, Drug Metabolite Or Substance With Description And Severity Of Significant Interactions Per Date Of Service	All

Page 22 of 99

0083U	Oncology, Response To Chemotherapy Drugs Using Motility Contrast Tomography, Fresh Or Frozen Tissue, Reported As	All
	Likelihood Of Sensitivity Or Resistance To Drugs Or Drug Combinations	
0084U	Red Blood Cell Antigen Typing, Dna, Genotyping Of 10 Blood Groups With Phenotype Prediction Of 37 Red Blood Cell Antigens	All
0085T	Algorithm Reported As A Rejection Risk Score.	T86.20-T86.298 Z48.21 Z94.1
0087U	Cardiology (Heart Transplant), Mrna Gene Expression Profiling By Microarray Of 1283 Genes, Transplant Biopsy Tissue, Allograft Rejection And Injury Algorithm Reported As A Probability Score	All
0088U	Transplantation Medicine (Kidney Allograft Rejection), Microarray Gene Expression Profiling Of 1494 Genes, Utilizing Transplant Biopsy Tissue, Algorithm Reported As A Probability Score For Rejection	All
0089U	Oncology (Melanoma), Gene Expression Profiling By Rtqpcr, Prame And Linc00518, Superficial Collection Using Adhesive Patch (Es)	All
0090U	Oncology (Cutaneous Melanoma), Mrna Gene Expression Profiling By Rt-Pcr Of 23 Genes (14 Content And 9 Housekeeping), Utilizing Formalin- Fixed Paraffin-Embedded Tissue, Algorithm Reported As A Categorical Result (Ie, Benign, Indeterminate, Malignant)	All
0091U	Oncology (Colorectal) Screening, Cell Enumeration Of Circulating Tumor Cells, Utilizing Whole Blood, Algorithm, For The Presence Of Adenoma Or Cancer, Reported As A Positive Or Negative Result	All

Page 23 of 99

000011	0 1 (1) TI D ()	All
0092U	Oncology (Lung), Three Protein	All
	Biomarkers, Immunoassay Using	
	Magnetic Nanosensor Technology,	
	Plasma, Algorithm Reported As Risk	
	Score For Likelihood Of Malignancy	
0095U	Inflammation (Eosinophilic	All
	Esophagitis), Elisa Analysis Of	
	Eotaxin-3 (Ccl26 [C-C Motif	
	Chemokine Ligand 26]) And Major	
	Basic Protein (Prg2 [Proteoglycan 2,	
	Pro Eosinophil Major Basic Protein]),	
	Specimen Obtained By Swallowed	
	Nylon String, Algorithm Reported As	
	Predictive Probability Index For	
	Active Eosinophilic Esophagitis	
097U	Gastrointestinal Pathogen, Multiplex	All
	Reverse Transcription And Multiplex	
	Amplified Probe Technique, Multiple	
	Types Or Subtypes, 22 Targets	
	(Campylobacter [C. Jejuni/C. Coli/C.	
	Upsaliensis], Clostridium Difficile [C.	
	Difficile] Toxin A/B, Plesiomonas	
	Shigelloides, Salmonella, Vibrio [V.	
	Parahaemolyticus/V. Vulnificus/V.	
	Cholerae], Including Specific	
	Identification Of Vibrio Cholerae,	
	Yersinia Enterocolitica,	
	Enteroaggregative Escherichia Coli	
	35 5	
	[Eaec], Enteropathogenic Escherichia	
	Coli [Epec], Enterotoxigenic	
	Escherichia Coli [Etec] Lt/St, Shiga-	
	Like Toxin-Producing Escherichia Coli	
	[Stec] Stx1/Stx2 [Including Specific	
	Identification Of The E. Coli 0157	
	Serogroup Within Stec],	
	Shigella/Enteroinvasive Escherichia	
	Coli [Eiec], Cryptosporidium,	
	Cyclospora Cayetanensis, Entamoeba	
	Histolytica, Giardia Lamblia [Also	
	Known As G. Intestinalis And G.	
	Duodenalis], Adenovirus F 40/41,	
	Astrovirus, Norovirus Gi/Gii, Rotavirus	
	A, Sapovirus [Genogroups I, Ii, Iv, And	
	V])	
	'])	

Page **24** of **99**

0100T	Placement Of A Subconjunctival Retinal Prosthesis Receiver And Pulse Generator, And Implantation Of Intra-Ocular Retinal Electrode Array, With Vitrectomy.	All
0101T	Extracorporeal Shock Wave Therapy; Involving Musculoskeletal System, Not Otherwise Specified; High Energy	M72.2 M75.20-M75.22 M77.00-M77.02 M77.10-M77.12 M84.311-M84.38 M87.051-M87.059
0101U	Hereditary Colon Cancer Disorders (Eg, Lynch Syndrome, Pten Hamartoma Syndrome, Cowden Syndrome, Familial Adenomatosis Polyposis), Genomic Sequence Analysis Panel Utilizing A Combination Of Ngs, Sanger, Mlpa, And Array Cgh, With Mrna Analytics To Resolve Variants Of Unknown Significance When Indicated (15 Genes [Sequencing And Deletion/Duplication], Epcam And Grem1 [Deletion/Duplication Only])	
0102T	Extracorporeal Shock Wave Therapy; High Energy, Performed By A Physician, Requiring Anesthesia Other Than Local, Involving Lateral Humeral Epicondyle.	M72.2 M75.20-M75.22 M77.00-M77.02 M77.10-M77.12 M84.311-M84.38 M87.051-M87.059
0102U	Hereditary Breast Cancer-Related Disorders (Eg, Hereditary Breast Cancer, Hereditary Ovarian Cancer, Hereditary Endometrial Cancer), Genomic Sequence Analysis Panel Utilizing A Combination Of Ngs, Sanger, Mlpa, And Array Cgh, With Mrna Analytics To Resolve Variants Of Unknown Significance When Indicated (17 Genes [Sequencing And Deletion/Duplication])	All

Page **25** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0103U	Hereditary Ovarian Cancer (Eg,	All
	Hereditary Ovarian Cancer,	
	Hereditary Endometrial Cancer),	
	Genomic Sequence Analysis Panel	
	Utilizing A Combination Of Ngs,	
	Sanger, Mlpa, And Array Cgh, With	
	Mrna Analytics To Resolve Variants Of	
	Unknown Significance When Indicated	
	(24 Genes [Sequencing And	
	Deletion/Duplication], Epcam	
	[Deletion/Duplication Only])	

Page **26** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0105U	Nephrology (Chronic Kidney Disease), Multiplex Electrochemiluminescent Immunoassay (Eclia) Of Tumor Necrosis Factor Receptor 1A, Receptor Superfamily 2 (Tnfr1, Tnfr2), And Kidney Injury Molecule-1 (Kim-1) Combined With Longitudinal Clinical Data, Including Apol1 Genotype If Available, And Plasma (Isolated Fresh Or Frozen), Algorithm Reported As Probability Score For Rapid Kidney Function Decline (Rkfd)	All
0106T	Quantitative Sensory Testing (Qst), Testing And Interpretation Per Extremity; Using Touch Pressure Stimuli To Assess Large Diameter Sensation	All
0106U	Gastric Emptying, Serial Collection Of 7 Timed Breath Specimens, Non- Radioisotope Carbon-13 (13C) Spirulina Substrate, Analysis Of Each Specimen By Gas Isotope Ratio Mass Spectrometry, Reported As Rate Of 13Co2 Excretion	All
0107T	Using Vibration Stimuli To Assess Large Diameter Fiber Sensation	All
0107U	Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
0108T	Using Cooling Stimuli To Assess Small Nerve Fiber Sensation And Hyperalgesia	All
0108U	Gastroenterology (Barrett'S Esophagus), Whole Slide-Digital Imaging, Including Morphometric Analysis, Computer-Assisted Quantitative Immunolabeling Of 9 Protein Biomarkers (P16, Amacr, P53, Cd68, Cox-2, Cd45Ro, Hif1A, Her- 2, K20) And Morphology, Formalin-Fixed Paraffin-Embedded Tissue, Algorithm Reported As Risk Of Progression To High-Grade Dysplasia Or Cancer	All

Page **27** of **99**

0109T	Using Heat-Pain StiQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia CONJUNCTION WITH CPT® CODE	All
0110T	Using Other Stimuli To Assess	All
	Sensation.	
0110U	Prescription Drug Monitoring, One Or More Oral Oncology Drug(S) And Substances, Definitive Tandem Mass Spectrometry With Chromatography, Serum Or Plasma From Capillary Blood Or Venous Blood, Quantitative Report With Steady-State Range For The Prescribed Drug(S) When Detected	All
0113U	Oncology (Prostate), Measurement Of Pca3 And Tmprss2-Erg In Urine And Psa In Serum Following Prostatic Massage, By Rna Amplification And Fluorescence- Based Detection, Algorithm Reported As Risk Score	All
0114U	Gastroenterology (Barrett's Esophagus), Vim And Ccna1 Methylation Analysis, Esophageal Cells, Algorithm Reported As Likelihood For Barrett'S Esophagus	All
0116U	Prescription Drug Monitoring, Enzyme Immunoassay Of 35 Or More Drugs Confirmed With Lc-Ms/Ms, Oral Fluid, Algorithm Results Reported As A Patient-Compliance Measurement With Risk Of Drug To Drug Interactions For Prescribed Medications	All

Page **28** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0117U	Pain Management, Analysis Of 11 Endogenous Analytes (Methylmalonic Acid, Xanthurenic Acid, Homocysteine, Pyroglutamic Acid, Vanilmandelate, 5- Hydroxyindoleacetic Acid, Hydroxymethylglutarate, Ethylmalonate, 3- Hydroxypropyl Mercapturic Acid (3-Hpma), Quinolinic Acid, Kynurenic Acid), Lc- Ms/Ms, Urine, Algorithm Reported As A Pain-Index Score With Likelihood Of Atypical Biochemical Function Associated With Pain	All
0118U	Transplantation Medicine, Quantification Of Donor-Derived Cell- Free Dna Using Whole Genome Next- Generation Sequencing, Plasma, Reported As Percentage Of Donor- Derived Cell- Free Dna In The Total Cell-Free Dna	All
0119U	Cardiology, Ceramides By Liquid Chromatography Tandem Mass Spectrometry, Plasma, Quantitative Report With Risk Score For Major Cardiovascular Events	All
0120U	Oncology (B-Cell Lymphoma Classification), Mrna, Gene Expression Profiling By Fluorescent Probe Hybridization Of 58 Genes (45 Content And 13 Housekeeping Genes), Formalin-Fixed Paraffin- Embedded Tissue, Algorithm Reported As Likelihood For Primary Mediastinal B-Cell Lymphoma (Pmbcl) And Diffuse Large B-Cell Lymphoma (Dlbcl) With Cell Of Origin Subtyping In The Latter	All
0121U	Sickle Cell Disease, Microfluidic Flow Adhesion (Vcam-1), Whole Blood	All
0122U	Sickle Cell Disease, Microfluidic Flow Adhesion (P-Selectin), Whole Blood	All

Page 29 of 99

0123U	Mechanical Fragility, Rbc, Shear Stress And Spectral Analysis Profiling	All
0126T	Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment	Z13.6
0129U	Hereditary Breast Cancer-Related Disorders (Eg, Hereditary Breast Cancer, Hereditary Ovarian Cancer, Hereditary Endometrial Cancer), Genomic Sequence Analysis And Deletion/Duplication Analysis Panel (Atm, Brca1, Brca2, Cdh1, Chek2, Palb2, Pten, And Tp53)	All
0130U	Hereditary Colon Cancer Disorders (Eg, Lynch Syndrome, Pten Hamartoma Syndrome, Cowden Syndrome, Familial Adenomatosis Polyposis), Targeted Mrna Sequence Analysis Panel (Apc, Cdh1, Chek2, Mlh1, Msh2, Msh6, Mutyh, Pms2, Pten, And Tp53) (List Separately In Addition To Code For Primary Procedure)	All
0131U	Hereditary Breast Cancer-Related Disorders (Eg, Hereditary Breast Cancer, Hereditary Ovarian Cancer, Hereditary Endometrial Cancer), Targeted Mrna Sequence Analysis Panel (13 Genes) (List Separately In Addition To Code For Primary Procedure)	All
0132U	Hereditary Ovarian Cancer-Related Disorders (Eg, Hereditary Breast Cancer, Hereditary Ovarian Cancer, Hereditary Endometrial Cancer), Targeted Mrna Sequence Analysis Panel (17 Genes) (List Separately In Addition To Code For Primary Procedure)	All
0133U	Hereditary Prostate Cancer-Related Disorders, Targeted Mrna Sequence Analysis Panel (11 Genes) (List Separately In Addition To Code For Primary Procedure)	All

Page 30 of 99

0134U	Hereditary Pan Cancer (Eg, Hereditary Breast And Ovarian Cancer, Hereditary Endometrial Cancer, Hereditary Colorectal Cancer), Targeted Mrna Sequence Analysis Panel (18 Genes) (List Separately In Addition To Code For Primary Procedure)	All
0135U	Hereditary Gynecological Cancer (Eg, Hereditary Breast And Ovarian Cancer, Hereditary Endometrial Cancer, Hereditary Colorectal Cancer), Targeted Mrna Sequence Analysis Panel (12 Genes) (List Separately In Addition To Code For Primary Procedure)	All
0136U	Atm (Ataxia Telangiectasia Mutated) (Eg, Ataxia Telangiectasia) Mrna Sequence Analysis (List Separately In Addition To Code For Primary Procedure)	All
0137U	Palb2 (Partner And Localizer Of Brca2) (Eg, Breast And Pancreatic Cancer) Mrna Sequence Analysis (List Separately In Addition To Code For Primary Procedure)	All
0138U	Brca1 (Brca1, Dna Repair Associated), Brca2 (Brca2, Dna Repair Associated) (Eg, Hereditary Breast And Ovarian Cancer) Mrna Sequence Analysis (List Separately In Addition To Code For Primary Procedure)	All
0152U	Infectious Disease (Bacteria, Fungi, Parasites, And Dna Viruses), Dna, Pcr And Next- Generation Sequencing, Plasma, Detection Of >1,000 Potential Microbial Organisms For Significant Positive Pathogens	All
0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	All

Page **31** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0156U	Copy Number (Eg, Intellectual Disability, Dysmorphology), Sequence Analysis	All
0163T	Total Disc Arthroplasty (Artificial Disc), Anterior Approach, Including Discectomy To Prepare Interspace (Other Than For Decompression), Each	All
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas	All
0164T	Additional Interspace, Lumbar (List Separately In Addition To Code For Primary Procedure)	All
0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti- vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results	All
0165T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	All
0165U	Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation	All

Page **32** of **99**

0166U	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	All
0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy	All
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	All
0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	All
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	All
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin- embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	All

Page **33** of **99**

	T =	
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)	All
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction	All
0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	All
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3- galactosyltransferase) gene, including subtyping, 7 exons	All
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1	All
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10	All
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19	All
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP- ribosyltransferase 4 [Dombrock blood group]) exon 2	All

Page **34** of **99**

0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4	All
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2	All
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2	All
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1- 4	All
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2	All
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3	All
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6	All
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9	All
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26	All
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo- endopeptidase [Kell blood group]) exon 8	All
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	All

Page **35** of **99**

0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3	All
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner- Wiener blood group]) exon 1	All
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5	All
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12	All
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3	All
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2	All
0202T	Posterior Vertebral Joint(S) Arthroplasty (Eg, Facet Joint[S] Replacement) Including Facetectomy, Laminectomy, Foraminotomy And Vertebral Column Fixation, Injection Of Bone Cement, When Performed, Including Fluoroscopy, Single Level, Lumbar Spine	All
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	All

Page **36** of **99**

	1	
0203U	Autoimmune (inflammatory bowel	All
	disease), mRNA, gene expression	
	profiling by quantitative RT-PCR,	
	17 genes (15 target and 2 reference	
	genes), whole blood, reported as a	
	continuous risk score and	
	classification of inflammatory	
	bowel disease aggressiveness	
0204U	Oncology (thyroid), mRNA, gene	All
	expression analysis of 593 genes	
	(including BRAF, RAS, RET, PAX8,	
	and NTRK) for sequence variants	
	and rearrangements, utilizing fine	
	needle aspirate, reported as	
	detected or not detected	
0205U		All
02030	Ophthalmology (age-related	All
	macular degeneration), analysis of	
	3 gene variants (2 CFH gene, 1	
	ARMS2 gene), using PCR and MALDI-	
	TOF, buccal swab, reported as	
	positive or negative for neovascular	
	age-related macular-degeneration	
	risk associated with zinc	
	supplements	
0206U	Neurology (Alzheimer disease); cell	All
	aggregation using morphometric	
	imaging and protein kinase C-	
	epsilon (PKCe) concentration in	
	response to amylospheroid	
	treatment by ELISA, cultured skin	
	fibroblasts, each reported as	
	positive or negative for Alzheimer	
	disease	
0207T	Evacuation Of Meibomian Glands,	H04.121-H04.129
02071	Automated, Using Heat And	1104.121 1104.127
	Intermittent Pressure, Unilateral.	
0207U	Neurology (Alzheimer disease);	All
02070		Att
	quantitative imaging of	
	phosphorylated ERK1 and ERK2 in	
	response to bradykinin treatment by	
	in situ immunofluorescence, using	
	cultured skin fibroblasts, reported as	
	a probability index for Alzheimer	
	disease (List separately in addition to	
	code for primary procedure)	

Page **37** of **99**

0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	All
0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	All
0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	All
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	All
0218U	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood orsaliva, identification and characterization of genetic variants	All

Page 38 of 99

0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	All
0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	All
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	All
0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	All
0225U	[Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected]	All
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation	All

Page **39** of **99**

0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	All
0229U	BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis	All
0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements	All
0243U	Obstetrics (preeclampsia), biochemical assay of placental- growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for	All
0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffinembedded tumor tissue	All
0247U	Obstetrics (preterm birth), insulin- like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	All

Page **40** of **99**

0248U 0249U	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	All
0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	All
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	All
0252U	Fetal aneuploidy short tandem?repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy	All
0253T	Insertion Of Anterior Segment Aqueous Drainage Device, Without Extraocular Reservoir, Internal Approach, Into The Suprachoroidal Space	All
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	All

Page **41** of **99**

0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	All
0258U	Autoimmune (psoriasis), mRNA, next- generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	All
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myoinositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	All
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	All
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	All
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalinfixed paraffin embedded (FFPE), algorithm reported as gene pathway activity score	All

Page **42** of **99**

0263T	Intramuscular Autologous Bone Marrow Cell Therapy, With Preparation Of Harvested Cells, Multiple Injections, One Leg, Including Ultrasound Guidance, If Performed; Complete Procedure Including Unilateral Or Bilateral Bone Marrow Harvest	
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, αketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	All
0264T	Intramuscular Autologous Bone Marrow Cell Therapy, With Preparation Of Harvested Cells, Multiple Injections, One Leg, Including Ultrasound Guidance, If Performed; Complete Procedure Excluding Bone Marrow Harvest	All
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	All
0265T	Intramuscular Autologous Bone Marrow Cell Therapy, With Preparation Of Harvested Cells, Multiple Injections, One Leg, Including Ultrasound Guidance, If Performed; Unilateral Or Bilateral Bone Marrow Harvest Only For Intramuscular Autologous Bone Marrow Cell Therapy.	All
0266T	Implantation Or Replacement Of Baroflex Activation Devices	All

Page **43** of **99**

02//!!	Hannalainad anaditutional anati	All
0266U	Unexplained constitutional or other	All
	heritable disorders or syndromes,	
	tissue specific gene expression by	
	whole transcriptome and next-	
	generation sequencing, blood,	
	formalin-fixed paraffin embedded	
	(FFPE) tissue or fresh frozen tissue,	
	reported as presence or absence of	
	splicing or expression changes	
0267T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	
0267U	Rare constitutional and other	All
	heritable disorders, identification	
	of copy number variations,	
	inversions, insertions,	
	translocations, and other structural	
	variants by optical genome	
	mapping and whole genome	
	sequencing	
0268T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	
0269T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	
0270T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	
0271T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	
0272T	Implantation Or Replacement Of	All
	Baroflex Activation Devices	7.55
0273T	Implantation Or Replacement Of	All
32/31	Baroflex Activation Devices	7
0274T	Percutaneous	All
	Laminotomy/Laminectomy	
	(Intralaminar Approach) For	
	Decompression Of Neural Elements	
	(With Or Without Ligamentous	
	Resection, Discectomy, Facetectomy	
	And/Or Foraminotomy), Any Method	
	Under Indirect Image Guidance (Eg,	
	Fluoroscopic, [Computed Tomography]	
	Ct), With Or Without The Use Of An	
	Endoscope, Single Or Multiple Levels,	
	Unilateral Or Bilateral; Cervical Or	
	Thoracic	

Page **44** of **99**

	Ta .	
0275T	Percutaneous	All
	laminotomy/laminectomy	
	(interlaminar approach) for	
	decompression of neural elements,	
	(with or without ligamentous	
	resection, discectomy, facetectomy	
	and/or foraminotomy), any method,	
	under indirect image guidance (eg,	
	fluoroscopic, CT), single or multiple	
00707	levels, unilateral or bilateral; lumbar	411
0278T	Transcutaneous Electrical Modulation	All
	Pain Reprocessing (Eg, Scrambler	
	Therapy), Each Treatment Session	
	(Includes Placement Of Electrodes)	
0278U	Hematology (genetic thrombosis),	All
	genomic sequence analysis of 12	
	genes, blood, buccal swab, or	
	amniotic fluid	
0279U	Hematology (von Willebrand	All
02/90	5 , \	Att
	disease [VWD]), von Willebrand	
	factor (VWF) and collagen III	
	binding by enzyme-linked	
	immunosorbent assays (ELISA),	
	plasma, report of collagen III	
	binding	
0280U	Hematology (von Willebrand	All
	disease [VWD]), von Willebrand	
	factor (VWF) and collagen IV	
	binding by enzyme-linked	
	immunosorbent assays (ELISA),	
	plasma, report of collagen IV	
	binding	
0281U	3	All
02810	Hematology (von Willebrand	All
	disease [VWD]), von Willebrand	
	propeptide, enzyme-linked	
	immunosorbent assays (ELISA),	
	plasma, diagnostic report of von	
	Willebrand factor (VWF) propeptide	
	antigen level	
0282U	Red blood cell antigen typing, DNA,	All
	genotyping of 12 blood group	
	system genes to predict 44 red	
	blood cell antigen phenotypes	
0283U	von Willebrand factor (VWF), type	All
02030	\ // 21	Att
	2B, platelet-binding evaluation,	
	radioimmunoassay, plasma	

Page **45** of **99**

0284U 0285U	von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme-linked immunosorbent assays (ELISA), plasma Oncology, response to radiation,	All
	cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	All
0289U	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score	All
0290U	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	All
0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score	All
0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	All
0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	All

Page **46** of **99**

	T	
0294U	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	All
0295U	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffinembedded (FFPE) tissue, algorithm reported as a recurrence risk score	All
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	All
0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	All
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	All

Page **47** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	All
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	All
0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	All
0304U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	All
0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	All
0312T	Vagus Nerve Blocking Therapy (Morbid Obesity); Laparoscopic Implantation Of Neurostimulator Electrode Array, Anterior And Posterior Vagal Trunks Adjacent To Esophagogastric Junction (Egj), With Implantation Of Pulse Generator, Includes Programming	All

Page 48 of 99

0313T	Laparoscopic Revision Or	All
	Replacement Of Vagal Trunk	
	Neurostimulator Electrode Array,	
	Including Connection To Existing	
	Pulse Generator	
0314T	Laparoscopic Removal Of Vagal	All
	Trunk Neurostimulator Electrode	
	Array And Pulse Generator	
0315T	Neurostimulator Pulse Generator	All
	Electronic Analysis, Includes	
	Reprogramming When Performed	
0316T	Replacement Of Pulse Generator	All
0317T	Neurostimulator Pulse Generator	All
	Electronic Analysis, Includes	
	Reprogramming When Performed	
0330T	Tear Film Imaging, Unilateral Or	H04.121-H04.129
	Bilateral, With Interpretation And	
	Report.	
0332T	Myocardial Sympathetic Innervation	150.1-150.9
	Imaging; Planar Qualitative And	
	Quantitative Assessment, And With	
	Tomographic Spect	
0335T	Insertion Of Sinus Tarsi Implant OR	All
	Extra-Osseous Subtalar Joint	
	Implant For Talotarsal Stabilization	
0338T	Transcatheter Renal Sympathetic	l10.0-l15.9
	Denervation, Percutaneous Approach	
	Including Arterial Puncture, Selective	
	Catheter Placement(S) Renal	
	Artery(les), Fluoroscopy, Contrast	
	Injection(S), Intraprocedural	
	Roadmapping And Radiological	
	Supervision And Interpretation,	
	Including Pressure Gradient	
	Measurements, Flush Aortogram And	
	Diagnostic Renal Angiography When	
	Performed; Unilateral: And Bilateral	

Page **49** of **99**

0220T	Transactions Development Company	140 145 0
0339T	Transcatheter Renal Sympathetic	I10-I15.9
	Denervation, Percutaneous Approach	
	Including Arterial Puncture, Selective	
	Catheter Placement(S) Renal	
	Artery(les), Fluoroscopy, Contrast	
	Injection(S), Intraprocedural	
	Roadmapping And Radiological	
	Supervision And Interpretation,	
	Including Pressure Gradient	
	Measurements, Flush Aortogram And	
	Diagnostic Renal Angiography When	
	Performed; Unilateral: And Bilateral	
030 IT	·	C 1 1 2 1 1 C 1 1 2 1 0 C 1 1 2 2 1
0394T	High Dose Rate Electronic	C44.211-C44.219 C44.221-
	Brachytherapy, Skin Surface	C44.299 C44.310-C44.319
	Application, Per Fraction, Includes	C44.320-C44.329 C44.41
	Basic Dosimetry, When Performed	C44.42
0397T	Endoscopic Retrograde	K22.70-K22.719
	Cholangiopancreatography (Ercp)	Z13.810 Z13.811 Z13.83
	With Optical Endomicroscopy	
0399T	Myocardial Strain Imaging	All
	(Quantitative Assessment Of	
	Myocardial Mechanics Using Image-	
	Based Analysis Of Local Myocardial	
	Dynamics) (List Separately In Addition	
	To Code For Primary Procedure)	
0400T	Multi-Spectral Digital Skin Lesion	C43.0-C43.9 D22.0-D22.9 D23.0-
04001	Analysis Of Clinically Atypical	D23.9
		DZ3.7
	Cutaneous Pigmented Lesions For	
	Detection Of Melanomas And High	
	Risk Melanocytic Atypia: One To Five	
0.40.47	Lesions	642.0.642.0
0401T	Multi-spectral digital skin lesion	C43.0-C43.9
	analysis of clinically atypical	D22.0-D22.9 D23.0-D23.9
	cutaneous pigmented lesions for	
	detection of melanomas and high risk	
	melanocytic atypia; six or more lesions	
0406T	Nasal Endoscopy, Surgical, Ethmoid	All
	Sinus, Placement Of Drug Eluting	
	Implant	
0407T	Nasal Endoscopy, Surgical, Ethmoid	All
	Sinus, Placement Of Drug Eluting	
	Implant; With Biopsy, Polypectomy	
	Or Debridement	
0449T		All
U4471	Insertion Of Aqueous Drainage Device,	All
	Without Extraocular Reservoir,	
	I INTORNAL ANDROACH INTO INC	
	Internal Approach, Into The Subconjunctival Space; Initial Device	

Page **50** of **99**

0450T	Insertion Of Aqueous Drainage Device, Without Extraocular Reservoir, Internal Approach, Into The Subconjunctival Space; Each Additional Device (List Separately In Addition To Code For Primary Procedure)	All
0506T	Macular Pigment Optical Density Measurement By Heterochromatic Flicker Photometry, Unilateral Or Bilateral, With Interpretation And Report	All
0507T	Near-Infrared Dual Imaging (Ie, Simultaneous Reflective And Trans- Illuminated Light) Of Meibomian Glands, Unilateral Or Bilateral, With Interpretation And Report	All
0508T	Pulse-Echo Ultrasound Bone Density Measurement Resulting In Indicator Of Axial Bone Mineral Density, Tibia	All
0509T	Electroretinography (Erg) With Interpretation And Report, Pattern (Perg)	All
0510T	Removal Of Sinus Tarsi Implant	All
0511T	Removal And Reinsertion Of Sinus Tarsi Implant	All
0512T	Extracorporeal Shock Wave For Integumentary Wound Healing, High Energy, Including Topical Application And Dressing Care; Initial Wound	All
0513T	Extracorporeal Shock Wave For Integumentary Wound Healing, High Energy, Including Topical Application And Dressing Care; Each Additional Wound (List Separately In Addition To Code For Primary Procedure)	All
0514T	Intraoperative Visual Axis Identification Using Patient Fixation (List Separately In Addition To Code For Primary Procedure)	All

Page **51** of **99**

0515T	Insertion Of Wireless Cardiac Stimulator For Left Ventricular Pacing, Including Device Interrogation And Programming, And Imaging Supervision And Interpretation, When Performed; Complete System (Includes Electrode And Generator [Transmitter And Battery])	All
0516T	Insertion Of Wireless Cardiac Stimulator For Left Ventricular Pacing, Including Device Interrogation And Programming, And Imaging Supervision And Interpretation, When Performed; Complete System (Includes Electrode And Generator [Transmitter And Battery])	All
0517T	Insertion Of Wireless Cardiac Stimulator For Left Ventricular Pacing, Including Device Interrogation And Programming, And Imaging Supervision And Interpretation, When Performed; Pulse Generator Component(S) (Battery And/Or Transmitter) Only	All
0518T	Removal Of Only Pulse Generator Component(S) (Battery And/Or Transmitter) Of Wireless Cardiac Stimulator For Left Ventricular Pacing	All
0519T	Removal And Replacement Of Wireless Cardiac Stimulator For Left Ventricular Pacing; Pulse Generator Component(S) (Battery And/Or Transmitter)	All
0520T	Removal And Replacement Of Wireless Cardiac Stimulator For Left Ventricular Pacing; Pulse Generator Component(S) (Battery And/Or Transmitter), Including Placement Of A New Electrode	All
0521T	Interrogation Device Evaluation (In Person) With Analysis, Review And Report, Includes Connection, Recording, And Disconnection Per Patient Encounter, Wireless Cardiac Stimulator For Left Ventricular Pacing	All

Page **52** of **99**

0522T	Programming Device Evaluation (In Person) With Iterative Adjustment Of The Implantable Device To Test The Function Of The Device And Select Optimal Permanent Programmed Values With Analysis, Including Review And Report, Wireless Cardiac Stimulator For Left Ventricular Pacing	All
0523T	Intraprocedural Coronary Fractional Flow Reserve (Ffr) With 3D Functional Mapping Of Color-Coded Ffr Values For The Coronary Tree, Derived From Coronary Angiogram Data, For Real-Time Review And Interpretation Of Possible Atherosclerotic Stenosis(Es) Intervention (List Separately In Addition To Code For Primary Procedure)	All
0524T	Endovenous Catheter Directed Chemical Ablation With Balloon Isolation Of Incompetent Extremity Vein, Open Or Percutaneous, Including All Vascular Access, Catheter Manipulation, Diagnostic Imaging, Imaging Guidance And Monitoring	All
0525T	Insertion Or Replacement Of Intracardiac Ischemia Monitoring System, Including Testing Of The Lead And Monitor, Initial System Programming, And Imaging Supervision And Interpretation; Complete System (Electrode And Implantable Monitor)	All
0526T	Insertion Or Replacement Of Intracardiac Ischemia Monitoring System, Including Testing Of The Lead And Monitor, Initial System Programming, And Imaging Supervision And Interpretation; Electrode Only	All

Page **53** of **99**

0527T	Insertion Or Replacement Of Intracardiac Ischemia Monitoring System, Including Testing Of The Lead And Monitor, Initial System Programming, And Imaging Supervision And Interpretation; Implantable Monitor Only	
0528T	Programming Device Evaluation (In Person) Of Intracardiac Ischemia Monitoring System With Iterative Adjustment Of Programmed Values, With Analysis, Review, And Report	All
0529T	Interrogation Device Evaluation (In Person) Of Intracardiac Ischemia Monitoring System With Analysis, Review, And Report	All
0530T	Removal Of Intracardiac Ischemia Monitoring System, Including All Imaging Supervision And Interpretation; Complete System (Electrode And Implantable Monitor)	All
0531T	Removal Of Intracardiac Ischemia Monitoring System, Including All Imaging Supervision And Interpretation; Electrode Only	All
0532T	Removal Of Intracardiac Ischemia Monitoring System, Including All Imaging Supervision And Interpretation; Implantable Monitor Only	All
0533T	Continuous Recording Of Movement Disorder Symptoms, Including Bradykinesia, Dyskinesia, And Tremor For 6 Days Up To 10 Days; Includes Set-Up, Patient Training, Configuration Of Monitor, Data Upload, Analysis And Initial Report Configuration, Download Review, Interpretation And Report	All
0534T	Continuous Recording Of Movement Disorder Symptoms, Including Bradykinesia, Dyskinesia, And Tremor For 6 Days Up To 10 Days; Set-Up, Patient Training, Configuration Of Monitor	All

Page **54** of **99**

0535T	Continuous Recording Of Movement Disorder Symptoms, Including Bradykinesia, Dyskinesia, And Tremor For 6 Days Up To 10 Days; Data Upload, Analysis And Initial Report Configuration	All
0536T	Continuous Recording Of Movement Disorder Symptoms, Including Bradykinesia, Dyskinesia, And Tremor For 6 Days Up To 10 Days; Download Review, Interpretation And Report	All
0541T	Myocardial Imaging By Magnetocardiography (Mcg) For Detection Of Cardiac Ischemia, By Signal Acquisition Using Minimum 36 Channel Grid, Generation Of Magnetic-Field Time-Series Images, Quantitative Analysis Of Magnetic Dipoles, Machine Learning-Derived Clinical Scoring, And Automated Report Generation, Single Study;	All
0542T	Myocardial Imaging By Magnetocardiography (Mcg) For Detection Of Cardiac Ischemia, By Signal Acquisition Using Minimum 36 Channel Grid, Generation Of Magnetic-Field Time-Series Images, Quantitative Analysis Of Magnetic Dipoles, Machine Learning-Derived Clinical Scoring, And Automated Report Generation, Single Study; Interpretation And Report	All
0543T	Transapical Mitral Valve Repair, Including Transthoracic Echocardiography, When Performed, With Placement Of Artificial Chordae Tendineae	All
0545T	Transcatheter Tricuspid Valve Annulus Reconstruction With Implantation Of Adjustable Annulus Reconstruction Device, Percutaneous Approach	All
0546T	Radiofrequency Spectroscopy, Real Time, Intraoperative Margin Assessment, At Time Of Partial Mastectomy, With Report	All

Page **55** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0547T	Bone-Material Quality Testing By Microindentation(S) Of The Tibia(S), With Results Reported As	All
0553T	A Score Percutaneous Transcatheter Placement Of Iliac Arteriovenous Anastomosis Implant, Inclusive Of All Radiological Supervision And Interpretation, Intraprocedural Roadmapping, And Imaging Guidance Necessary To Complete The Intervention	All
0554T	Bone Strength And Fracture Risk Using Finite Element Analysis Of Functional Data, And Bone-Mineral Density, Utilizing Data From A Computed Tomography Scan; Retrieval And Transmission Of The Scan Data, Assessment Of Bone Strength And Fracture Risk And Bone Mineral Density, Interpretation And Report	All
0555T	Bone Strength And Fracture Risk Using Finite Element Analysis Of Functional Data, And Bone- Mineral Density, Utilizing Data From A Computed Tomography Scan; Retrieval And Transmission Of The Scan Data	All
0556T	Bone Strength And Fracture Risk Using Finite Element Analysis Of Functional Data, And Bone-Mineral Density, Utilizing Data From A Computed Tomography Scan; Assessment Of Bone Strength And Fracture Risk And Bone Mineral Density	All
0557T	Bone Strength And Fracture Risk Using Finite Element Analysis Of Functional Data, And Bone- Mineral Density, Utilizing Data From A Computed Tomography Scan; Interpretation And Report	All
0558T	Computed Tomography Scan Taken For The Purpose Of Biomechanical Computed Tomography Analysis	All

Page **56** of **99**

0559T	Anatomic Model 3D-Printed From Image Data Set(S); First Individually Prepared And Processed Component Of An Anatomic Structure	All
0560T	Anatomic Model 3D-Printed From Image Data Set(S); Each Additional Individually Prepared And Processed Component Of An Anatomic Structure (List Separately In Addition To Code For Primary Procedure)	All
0561T	Anatomic Guide 3D-Printed And Designed From Image Data Set(S); First Anatomic Guide	
0562T	Anatomic Guide 3D-Printed And Designed From Image Data Set(S); Each Additional Anatomic Guide (List Separately In Addition To Code For Primary Procedure)	All
0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral (For evacuation of meibomian gland using manual gland expression only	H04.121-H04.129
0564T	Oncology, Chemotherapeutic Drug Cytotoxicity Assay Of Cancer Stem Cells (Cscs), From Cultured Cscs And Primary Tumor Cells, Categorical Drug Response Reported Based On Percent Of Cytotoxicity Observed, A Minimum Of 14 Drugs Or Drug Combinations	All
0565T	Autologous Cellular Implant Derived From Adipose Tissue For The Treatment Of Osteoarthritis Of The Knees; Tissue Harvesting And Cellular Implant Creation	All
0566T	Injection Of Cellular Implant Into Knee Joint Using Ultrasound Guidance, Unilateral	All
0567T	Permanent Fallopian Tube Occlusion With Degradable Temporary Biopolymer Implant, Trans-Cervical Approach, Including Transvaginal Ultrasound	All

Page **57** of **99**

0568T	Introduction Of Mixture Of Saline And Air For Sonosalpingography To Confirm Occlusion Of Fallopian	All
0569T	Transcatheter Tricuspid Valve Repair, Percutaneous Approach; Initial Prosthesis	All
0570T	Each Additional Prosthesis During Same Session (List Separately	All
0581T	Ablation, Malignant Breast Tumor(S), Percutaneous, Cryotherapy, Including Imaging Guidance When Performed, Unilateral	All
0582T	Transurethral Ablation Of Malignant Prostate Tissue By Direct Current Heated High Energy Water Vapor Thermotherapy, Including Intraoperative Imaging And Needle Guidance	All
0583T	Tympanostomy (Requiring Insertion Of Ventilating Tube), Using An Automated Tube Delivery System, Iontophoresis Local Anesthesia	All
0587T	Percutaneous Implantation Or Replacement Of Integrated Neurostimulation System Including Electrode Array And Receiver Or Pulse Generator, Including Analysis, Programming, And Imaging Guidance When Performed, Posterior Tibial Nerve	All
0588T	Revision Or Removal Of Integrated Neurostimulation System Including Electrode Array And Receiver Or Pulse Generator, Including Analysis, Programming, And Imaging Guidance When Performed, Posterior Tibial Nerve	All

Page **58** of **99**

		· ·
0589T	Electronic Analysis With Simple Programming Of Implanted Integrated Neurostimulation System (Eg, Electrode Array And Receiver), Including Contact Group[S], Amplitude, Pulse Width, Frequency [Hz], On/Off Cycling, Burst, Dose Lockout, Patient Selectable Parameters, Responsive Neurostimulation, Detection Algorithms, Closed-Loop Parameters, And Passive Parameters When Performed By Physician Or Other Qualified Health Care Professional,	All
	Posterior Tibial Nerve, 1-3 Parameters	
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	All
0594T	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device	All
0596T	Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement	All
0597T	Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement	All

Page **59** of **99**

0598T	Noncontact real-time fluorescence	All
	wound imaging, for bacterial	
	presence, location, and load, per	
	session; first anatomic site (eg, lower	
OFOOT	extremity)	All
0599T	Noncontact real-time fluorescence	All
	wound imaging, for bacterial	
	presence, location, and load, per session; each additional anatomic	
	site (eg, upper extremity) (List	
	separately in addition to code for	
	primary procedure)	
0602T	Glomerular filtration rate (GFR)	All
	measurement(s), transdermal,	
	including sensor placement and	
	administration of a single dose of	
	fluorescent pyrazine agent	
0603T	Glomerular filtration rate (GFR)	All
	monitoring, transdermal, including	
	sensor placement and administration	
	of more than one dose of fluorescent	
	pyrazine agent, each 24 hours	
0604T	Optical coherence tomography (OCT)	All
	of retina, remote, patient-initiated	
	image capture and transmission to a	
	remote surveillance center unilateral	
	or bilateral; initial device provision, set-up and patient education on use	
	of equipment	
0605T	Optical coherence tomography (OCT)	All
00001	of retina, remote, patient-initiated	7.00
	image capture and transmission to a	
	remote surveillance center unilateral	
	or bilateral; remote surveillance	
	center technical support, data	
	analyses and reports, with a minimum	
	of 8 daily recordings, each 30 days	
0606T	Optical coherence tomography (OCT)	All
	of retina, remote, patient-initiated	
	image capture and transmission to a	
	remote surveillance center unilateral	
	or bilateral; review, interpretation	
	and report by the prescribing	
	physician or other qualified health	
	care professional of remote	
	surveillance center data analyses, each 30 days	
	Tacii 30 days	

Page **60** of **99**

0607T	Remote monitoring of an external	All
	continuous pulmonary fluid	
	monitoring system, including	
	measurement of radiofrequency-	
	derived pulmonary fluid levels,	
	heart rate, respiration rate,	
	activity, posture, and	
	cardiovascular rhythm (eg, ECG	
	data), transmitted to a remote 24-	
	hour attended surveillance center;	
	set-up and patient education on	
	use of equipment	
0608T	Remote monitoring of an external	All
00001	_	Att
	continuous pulmonary fluid	
	monitoring system, including	
	measurement of radiofrequency-	
	derived pulmonary fluid levels, heart	
	rate, respiration rate, activity,	
	posture, and cardiovascular rhythm	
	(eg, ECG data), transmitted to a	
	remote 24-hour attended surveillance	
	center; analysis of data received and	
	transmission of reports to the	
	physician or other qualified health	
	care professional	
0609T	Magnetic resonance spectroscopy,	All
	determination and localization of	
	discogenic pain (cervical, thoracic,	
	or lumbar); acquisition of single	
	Lyoyol data por disc on biomarkors	
	voxel data, per disc, on biomarkers	
	(ie, lactic acid, carbohydrate,	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid,	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at	
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy,	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic,	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic,	All
0610T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software	All
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis	
0610T 0611T	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy,	All
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic,	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker	
	(ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for	

Page **61** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

0612T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report	All
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed	All
0614T	Removal and replacement of substernal implantable defibrillator pulse generator	All
0615T	Eye-movement analysis without spatial calibration, with interpretation and report	
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed	All
0620T	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed	All
0621T	Trabeculostomy ab interno by laser	All
0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	All

Page **62** of **99**

0623T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed	All
	tomographic angiography; data	
	preparation and transmission,	
	computerized analysis of data, with review of computerized analysis	
	output to reconcile discordant data,	
	interpretation and report	
0624T	Automated quantification and	All
	characterization of coronary	
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography; data	
0625T	preparation and transmission Automated quantification and	All
00231	characterization of coronary	Att
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography;	
	computerized analysis of data from	
	coronary computed tomographic	
0626T	angiography	All
00201	Automated quantification and characterization of coronary	All
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography; review of	
	computerized analysis output to	
	reconcile discordant data,	
0627T	interpretation and report	All
0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product,	All
	intervertebral disc, unilateral or	
	bilateral injection, with fluoroscopic	
	guidance, lumbar; first level	

Page **63** of **99**

0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure) Percutaneous injection of allogeneic	All
	cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	All
0631T	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	All
0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	All
0633T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	All
0634T	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	All
0635T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)	All

Page **64** of **99**

0636T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)	All
0637T	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)	All
0638T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)	All
0639T	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed	All
0640T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound	All
0641T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition only, each flap or wound	All
0642T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound	All
0643T	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach	All

Page **65** of **99**

0646T	Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	All
0647T	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	All
0648T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session	All
0649T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	All
0652T	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	All
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple	All

Page **66** of **99**

	Te :	T
0654T	Esophagogastroduodenoscopy,	All
	flexible, transnasal; with insertion	
	of intraluminal tube or catheter	
0655T	Transperineal focal laser ablation	All
	of malignant prostate tissue,	
	including transrectal imaging	
	guidance, with MR-fused images or	
	other enhanced ultrasound imaging	
0656T	Vertebral body tethering, anterior;	All
	up to 7 vertebral segments	
0657T	Vertebral body tethering, anterior;	All
	8 or more vertebral segments	
0658T	Electrical impedance spectroscopy	All
	of 1 or more skin lesions for	
	automated melanoma risk score	
0659T	Transcatheter intracoronary	All
	infusion of supersaturated oxygen	
	in conjunction with percutaneous	
	coronary revascularization during	
	acute myocardial infarction,	
	including catheter placement,	
	imaging guidance (eg, fluoroscopy),	
	angiography, and radiologic	
	supervision and interpretation	
0660T	Implantation of anterior segment	All
	intraocular nonbiodegradable drug-	
	eluting system, internal approach	
0661T	Removal and reimplantation of	All
	anterior segment intraocular	
	nonbiodegradable drug-eluting	
	implant	
0664T	Donor hysterectomy (including cold	All
	preservation); open, from cadaver	
	donor	
0665T	Donor hysterectomy (including cold	All
	preservation); open, from living	
	donor	
0666T	Donor hysterectomy (including cold	All
	preservation); laparoscopic or	
	robotic, from living donor	
0667T	Donor hysterectomy (including cold	All
	preservation); recipient uterus	
	allograft transplantation from	
	cadaver or living donor	
	<u>, , , , , , , , , , , , , , , , , , , </u>	<u> </u>

Page **67** of **99**

0668T	Backbench standard preparation of	All
	cadaver or living donor uterine	
	allograft prior to transplantation,	
	including dissection and removal of	
	surrounding soft tissues and	
	preparation of uterine vein(s) and	
	uterine artery(ies), as necessary	
0669T	Backbench reconstruction of	All
00071	cadaver or living donor uterus	Att
	allograft prior to transplantation;	
	venous anastomosis, each	
0670T	,	All
00701	Backbench reconstruction of	Att
	cadaver or living donor uterus	
	allograft prior to transplantation;	
04707	arterial anastomosis, each	A.I.
0672T	Endovaginal cryogen-cooled,	All
	monopolar radiofrequency remodeling	
	of the tissues surrounding the female	
	bladder neck and proximal urethra for	
	urinary incontinence	
0673T	1 10 10 10 10 10 10 10 10 10 10 10 10 1	All
	percutaneous, laser, including imaging	
	guidance	
0674T	Laparoscopic insertion of new or	All
	replacement of permanent	
	implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
	including an implantable pulse	
	generator and diaphragmatic lead(s)	
0675T	Laparoscopic insertion of new or	All
	replacement of diaphragmatic lead(s),	
	permanent implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
	including connection to an existing	
	pulse generator; first lead	
0676T	Laparoscopic insertion of new or	All
	replacement of diaphragmatic lead(s),	
	permanent implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
	including connection to an existing	
	including connection to an existing	
	pulse generatoreach additional lead	

Page **68** of **99**

0677T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized	All
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
	including connection to an existing	
	pulse generator; first repositioned lead	
0678T	Laparoscopic repositioning of	All
	diaphragmatic lead(s), permanent	
	implantable synchronized	
	diaphragmatic stimulation system for augmentation of cardiac function,	
	including connection to an existing	
	pulse generatoreach additional	
	repositioned lead (List separately in	
	addition to code for primary	
	procedure)	
0679T	Laparoscopic removal of	All
	diaphragmatic lead(s), permanent	
	implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function	
0680T	Insertion or replacement of pulse	All
	generator only, permanent	
	implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
0681T	with connection to existing lead(s) Relocation of pulse generator only,	All
00011	permanent implantable synchronized	Att
	diaphragmatic stimulation system for	
	augmentation of cardiac function,	
	with connection to existing dual leads	
0682T	Removal of pulse generator only,	All
	permanent implantable synchronized	
	diaphragmatic stimulation system for	
	augmentation of cardiac function	
0683T	Programming device evaluation (in-	All
	person) with iterative adjustment of	
	the implantable device to test the	
	function of the device and select	
	optimal permanent programmed	
	values with analysis, review and	
	report by a physician or other qualified health care professional,	
	permanent implantable synchronized	
	diaphragmatic stimulation system for	
	anaphiraginatic stillutation system for	

Page **69** of **99**

	augmentation of cardiac function	
0684T	Peri-procedural device evaluation (in- person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	All
0685T	Interrogation device evaluation (in- person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	All
0686T	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance	All
0687T	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session	All
0688T	Treatment of amblyopia using an online digital programassessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month	All
0689T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)	All
0690T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	All

Page **70** of **99**

	1	
0691T	Automated analysis of an existing	All
	computed tomography study for	
	vertebral fracture(s), including	
	assessment of bone density when	
	performed, data preparation,	
0403T	interpretation, and report	A 1 1
0693T	Comprehensive full body computer-	All
	based markerless 3D kinematic and	
0404T	kinetic motion analysis and report	A11
0694T	3-dimensional volumetric imaging and	All
	reconstruction of breast or axillary	
	lymph node tissue, each excised	
	specimen, 3-dimensional automatic	
	specimen reorientation, interpretation	
04057	and report, realtime intraoperative	A.I.
0695T	Body surface-activation mapping of	All
	pacemaker or pacing cardioverter-	
	defibrillator lead(s) to optimize	
	electrical synchrony, cardiac	
	resynchronization therapy device,	
	including connection, recording,	
	disconnection, review, and report; at	
0/0/T	time of implant or replacement	A11
0696T	Body surface-activation mapping of	All
	pacemaker or pacing cardioverter-	
	defibrillator lead(s) to optimize	
	electrical synchrony, cardiac	
	resynchronization therapy device,	
	including connection, recording,	
	disconnection, review, and report; at time of follow-up interrogation or	
	programming device evaluation	
0697T	<u> </u>	All
00971	analysis of tissue composition (eg, fat,	Att
	iron, water content), including	
	multiparametric data acquisition, data	
	preparation and transmission,	
	interpretation and report, obtained	
	without diagnostic MRI examination of	
	the same anatomy (eg, organ, gland,	
	tissue, target structure) during the	
	same session; multiple organs	
0698T	<u> </u>	All
00701	Quantitative magnetic resonance for	All
	analysis of tissue composition (eg, fat, iron, water content), including	
	multiparametric data acquisition, data	
	preparation and transmission,	
	interpretation and report, obtained	
	interpretation and report, obtained	

Page **71** of **99**

	with diagnostic MRI examination of the same anatomy (eg, organ, gland,	
	tissue, target structure); multiple organs (List separately in addition to code for primary procedure)	
0700T	Molecular fluorescent imaging of suspicious nevus; first lesion	All
0701T	Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)	All
0702T	Remote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; supply and technical support, per 30 days	All
0703T	Remote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; management services by physician or other qualified health care professional, per calendar month	All
0704T	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment	All
0705T	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days	All
0706T	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month	All
0707T	Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization	All

Page **72** of **99**

0708T	Intradermal cancer immunotherapy; preparation and initial injection	All
0709T	Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)	All
0710T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report	All
0711T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission	All
0712T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability	All
0713T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report	All
15780	Dermabrasion; Total Face (Eg, For Acne Scarring, Fine Wrinkling, Rhytids, General Keratosis)	L71.0-L71.9
15781	Dermabrasion; Segmental, Face	L71.0-L71.9
15782	Dermabrasion; Regional, Other Than Face	L71.0-L71.9
15783	Dermabrasion; Superficial, Any Site, (Eg, Tattoo Removal)	L71.0-L71.9
15788	Chemical Peel, Facial; Epidermal	L71.0-L71.9
15789	Chemical Peel, Facial; Dermal	L71.0-L71.9
15792	Chemical Peel, Nonfacial; Epidermal	L71.0-L71.9

Page **73** of **99**

15793	Chemical Peel, Nonfacial; Dermal	L71.0-L71.9
15824	Rytidectomy	G43.001-G43.919
		G44.0-G44.89
15826	Glabellar Frown Lines	G43.001-G43.919 G44.0-G44.89
17000	Destruction By Any Method, Including	L71.0-L71.9
	Laser, With Or Without Surgical	
.=	Curettement, All Benign Or Pr	
17003	Destruction By Any Method, Including	L71.0-L71.9
	Laser, With Or Without Surgical Curettement, All Benign Or Pr	
17004	Destruction By Any Method, Including	L71.0-L71.9
17004	Laser, With Or Without Surgical	L/1.0-L/1.9
	Curettement, All Benign Or Pr	
17106	Destruction Of Cutaneous Vascular	L71.0-L71.9
17100	Proliferative Lesions (Eg, Laser	271.0 271.7
	Technique); Less Than 10 Sq Cm	
17107	Destruction Of Cutaneous Vascular	L71.0-L71.9
	Proliferative Lesions (Eg, Laser	
	Technique); 10.0 - 50.0 Sq Cm	
17108	Destruction Of Cutaneous Vascular	L71.0-L71.9
	Proliferative Lesions (Eg, Laser	
20540	Technique); Over 50.0 Sq Cm	All
20560	Needle Insertion(S) Without	All
20561	Injection(S); 1 Or 2 Muscle(S) Needle Insertion(S) Without	All
20301	Injection(S); 3 Or More Muscles	Att
20974	Electrical Stimulation To Aid Bone	M43.22
	Healing; Noninvasive (Non-Operative)	
20975	Electrical Stimulation to Aid Bone	M43.15-M43.17 M48.05-M48.07
	Healing; Incvasive (Operative)	M51.04-M51.9
22526	Percutaneous Intradiscal	All
	Electrothermal Annuloplasty,	
	Unilateral Or Bilateral Including	
22527	Fluoroscopic Guidance; Single Level	All
22527	Or More Additional Levels (List	All
	Separately In Addition To Code For Primary Procedure	
22857	Total Disc Arthroplasty (Artificial	All
22037	Disc), Anterior Approach, Including	Att
	Discectomy To Prepare Interspace	
	(Other Than For Decompression),	
	Single Interspace, Lumbar	
22862	Revision Including Replacement Of	All
	Total Disc Arthroplasty (Artificial	
	Disc), Anterior Approach, Single	
	Interspace; Lumbar	

Page **74** of **99**

22867	Insertion Of Interlaminar/Interspinous Process Stabilization/Distraction Device, Without Fusion, Including Image Guidance When Performed, With Open Decompression, Lumbar; Single Level Second Level (List Separately In Addition To Code For Primary Procedure	All
22868	Second Level (List Separately In Addition To Code For Primary Procedure	All
22869	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	All
22870	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)	All
28890	Extracorporeal Shock Wave, High Energy, Performed By A Physician, Requiring Anesthesia Other Than Local, Including Ultrasound Guidance, Involving The Plantar Fascia	M72.2 M75.20-M75.22 M77.00-M77.02 M77.10-M77.12 M84.311-M84.38 M87.051-M87.059
30130	Excision Inferior Turbinate Partial Or Complete, Any Method	G43.001-G43.919 G44.0-G44.89
30140	Submucous Resection Inferior Turbinate, Partial Or Complete, Any Method	G43.001-G43.919 G44.0-G44.89
30468	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)	All
30520	Septoplasty Or Submucous Resection, With Or Without Cartilage Scoring, Contouring Or Replacement With Graft	
30660	Bronchoscopy, Rigid Or Flexible, Including Fluoroscopic Guidance, When Performed; With Bronchial Thermoplasty, 1 Lobe	All
30661	With Bronchial Thermoplasty, 2 Or More Lobes	All

Page **75** of **99**

31626	Bronchoscopy, Rigid Or Flexible, Including fluoroscopic Guidance, When Performed; Withplacement Of Fiducial Markers, Single Or Multiple	C34.00- C34.92
31627	Bronchoscopy, Rigid Or Flexible, Including fluoro-Scopic Guidance, When Performed; Withcomputer- Assisted, Image- Guided Navigation (List Separately In Addition To Code For Primary	C34.00- C34.92
31647	Bronchoscopy, Rigid Or Flexible, Including Fluoroscopic Guidance, When Performed; With Balloon Occlusion, When Performed, Assessment Of Air Leak, Airway Sizing, And Insertion Of Bronchial Valve(S), Initial Lobe	All
31648	With Removal Of Bronchial Valve(S), Initial Lobe	All
31649	With Removal Of Bronchial Valve(S), Each Additional Lobe (List Separately In Addition To Code For Primary Procedure).	All
31651	With Balloon Occlusion, When Performed, Assessment Of Air Leak, Airway Sizing, And Insertion Of Bronchial Valve(S), Each Additional Lobe (List Separately In Addition To Code For Primary Procedure[S])	All
31660	Bronchoscopy, Rigid Or Flexible, Including Fluoroscopic Guidance, When Performed; With Bronchial Thermoplasty, 1 Lobe	All
31661	With Bronchial Thermoplasty, 2 Or More Lobes	All
33274	Transcatheter Insertion Or Replacement Of Permanent Leadless Pacemaker, Right Ventricular, Including Imaging Guidance (Eg, Fluoroscopy, Venous Ultrasound, Ventriculography, Femoral Venography) And Device Evaluation (Eg, Interrogation Or Programming), When Performed	All
33275	Transcatheter Removal Of Permanent Leadless Pacemaker, Right Ventricular	All

Page **76** of **99**

33289	Transcatheter Implantation Of Wireless Pulmonary Artery Pressure Sensor For Long- Term Hemodynamic Monitoring, Including Deployment And Calibration Of The Sensor, Right Heart Catheterization, Selective Pulmonary Catheterization, Radiological Supervision And Interpretation, And Pulmonary Artery Angiography, When Performed	All
33370	Transcatheter placement and removal of a cerebral embolic protection device	All
33548	Surgical Ventricular Restoration Procedure, Includes Prosthetic Patch, When Performed (Eg, Ventricular Remodeling, Svr, Saver, Dor Procedures)	125.3 125.5 142.0
34701	Endovascular Repair Of Infrarenal Aorta By Deployment Of An Aorto-Aortic Tube Endograft Including Pre-Procedure Sizing And Device Selection, All Nonselective Catheterization(S), All Associated Radiological Supervision And Interpretation, All Endograft Extension(S) Placed In The Aorta From The Level Of The Renal Arteries To The Aortic Bifurcation, And All Angioplasty/Stenting Performed From The Level Of The Renal Arteries To The Aortic Bifurcation; For Other Than Rupture (Eg, For Aneurysm, Pseudoaneurysm, Dissection, Penetrating Ulcer)	I71.00-I71.9

Page **77** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

34702	Endovascular Repair Of Infrarenal	I71.00-I71.9
1	Aorta By Deployment Of An Aorto-	
	Aortic Tube Endograft Including Pre-	
	Procedure Sizing And Device	
	Selection, All Nonselective	
	Catheterization(S), All Associated	
	Radiological Supervision And	
	Interpretation, All Endograft	
	Extension(S) Placed In The Aorta From	
	The Level Of The Renal Arteries To	
	The Aortic Bifurcation, And All	
	Angioplasty/Stenting Performed From	
	The Level Of The Renal Arteries To	
	The Aortic Bifurcation; For Rupture	
	Including Temporary Aortic And/Or	
	Iliac Balloon Occlusion, When	
	Performed (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection,	
	Penetrating Ulcer, Traumatic	
	Disruption)	
34703	Endovascular Repair Of Infrarenal	171.00-171.9
	Aorta And/Or Iliac Artery(Ies) By	
	Deployment Of An Aorto- Uni-Iliac	
	Endograft Including Pre-Procedure	
	Sizing And Device Selection, All	
	Nonselective Catheterization(S), All	
	Associated Radiological Supervision	
	And Interpretation, All Endograft	
	Extension(S) Placed In The Aorta From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation, And All	
	Angioplasty/Stenting Performed From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation; For Other Than	
	Rupture (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection,	
1	Penetrating Ulcer)	

Page **78** of **99**

34704	Endovascular Repair Of Infrarenal	I71.00-I71.9
	Aorta And/Or Iliac Artery(les) By	
	Deployment Of An Aorto-Uni- Iliac	
	Endograft Including Pre-Procedure	
	Sizing And Device Selection, All	
	Nonselective Catheterization(S), All	
	Associated Radiological Supervision	
	And Interpretation, All Endograft	
	Extension(S) Placed In The Aorta From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation, And All	
	Angioplasty/Stenting Performed From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation; For Rupture	
	Including Temporary Aortic And/Or	
	Iliac Balloon Occlusion, When	
	Performed (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection,	
	Penetrating Ulcer, Traumatic	
	Disruption)	
34705	Endovascular Repair Of Infrarenal	I71.00-I71.9
	Aorta And/Or Iliac Artery(les) By	
	Deployment Of An Aorto-Bi- Iliac	
	Endograft Including Pre-Procedure	
	Sizing And Device Selection, All	
	Nonselective Catheterization(S), All	
	Associated Radiological Supervision	
	And Interpretation, All Endograft	
	Extension(S) Placed In The Aorta From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation, And All	
	Angioplasty/Stenting Performed From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation; For Other Than	
	Rupture (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection, Penetrating Ulcer)	
1	- Panalitalino lilitari	

Page **79** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

34706	Endovascular Repair Of Infrarenal	171.00-171.9
	Aorta And/Or Iliac Artery(Ies) By	
	Deployment Of An Aorto-Bi- Iliac	
	Endograft Including Pre-Procedure	
	Sizing And Device Selection, All	
	Nonselective Catheterization(S), All	
	Associated Radiological Supervision	
	And Interpretation, All Endograft	
	Extension(S) Placed In The Aorta From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation, And All	
	Angioplasty/Stenting Performed From	
	The Level Of The Renal Arteries To	
	The Iliac Bifurcation; For Rupture	
	Including Temporary Aortic And/Or	
	Iliac Balloon Occlusion, When	
	Performed (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection,	
	Penetrating Ulcer, Traumatic	
	Disruption)	
34707	Endovascular Repair Of Iliac Artery	I71.00-I71.9
	By Deployment Of An Ilio-Iliac Tube	
	Endograft Including Pre-Procedure	
	Sizing And Device Selection, All	
	Nonselective Catheterization(S), All	
	Associated Radiological Supervision	
	And Interpretation, And All	
	Endograft Extension(S) Proximally	
	To The Aortic Bifurcation And	
	Distally To The Iliac Bifurcation,	
	And Treatment Zone	
	Angioplasty/Stenting, When	
	Performed, Unilateral; For Other	
	Than Rupture (Eg, For Aneurysm,	
	Pseudoaneurysm, Dissection,	
	Arteriovenous Malformation)	

Page **80** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

34708	Endovascular Repair Of Iliac Artery By Deployment Of An Ilio-Iliac Tube Endograft Including Pre-Procedure Sizing And Device Selection, All Nonselective Catheterization(S), All Associated Radiological Supervision And Interpretation, And All Endograft Extension(S) Proximally To The Aortic Bifurcation And Distally To The Iliac Bifurcation, And Treatment Zone Angioplasty/Stenting, When Performed, Unilateral; For Rupture Including Temporary Aortic And/Or Iliac Balloon Occlusion, When Performed (Eg, For Aneurysm, Pseudoaneurysm, Dissection, Arteriovenous Malformation, Traumatic Disruption)	I71.00-I71.9
36012	Selective Catheter Placement, Venous System; Second Order, Or More Selective, Branch (Eg, Left Adrenal vein, petrosal sinus)	N94.89
37241	Vascular Embolization Or Occlusion Inclusive Of All Radiological Supervision And Interpretation Intraprocedural Roadmapping And Imaging Guidance Necessary To Complete The Intervention; Venous Other	N94.89
38242	Allogeneic Donor Lymphocyte Infusions	C81.00-C96.9
41512	Tongue Base Suspension, Permanent Suture Technique	G47.09-G47.39
42975	Diagnostic sleep endoscopy with evaluation of velum, pharynx, tongue base, and larynx	All
43201	Esophagoscopy, Rigid Or Flexible; With Directed Submucosal Injection(S), Any Substance	K21.0 K21.9
43206	Esophagoscopy Rigid Or Flexible; With Optical Endomicroscopy	K22.70-K22.719 Z13.810 Z13.811 Z13.83
43210	Esophagogastroduodenoscopy Flexible Transoral; With Esophagogastric Fundoplasty Partial Or Complete Includes Duodenoscopy When Performed	K21.0 K21.9

Page **81** of **99**

	1	1/2 / 2 1/2 / 2
43212	Esophagoscopy Flexible Transoral; With Placementof Endoscopic Stent (Includes Pre- And Post-Dilation And Guide Wire Passage When Performed)	K21.0 K21.9
43252	Upper Gastrointestinal Endoscopy Including Esophagus Stomach And Either The Duodenum And/Or Jejunumas Appropriate; With Optical Endomicroscopy	K22.70-K22.719 Z13.810 Z13.811 Z13.83
43257	Esophagogastroduodenoscopy Flexible Transoral; With Delivery Of Thermal Energy To The Muscle Of Lower Esophageal Sphincter And/Or Gastric Cardia For Treatment Of Gastroesophageal Reflux Disease	K21.0 K21.9
43284	Laparoscopy Surgical Esophageal Sphincter Augmentation Procedure Placement Of Sphincter Augmentation Device (Ie Magnetic Band) Including Cruroplasty When Performed	K21.0 K21.9
43285	Removal Of Esophageal Sphincter Augmentation Device	K21.0 K21.9
43497	Lower esophageal myotomy, transoral	All
43647	Laparoscopy, Surgical; Implantation Or Replacement Of Gastric Neurostimulator Electrodes, Antrum	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
43648	Revision Or Removal Of Gastric Neurostimulator Electrodes, Antrum	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
43881	Implantation Or Replacement Of Gastric Neurostimulator Electrodes, Antrum, Open	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
43882	Revision Or Removal Of Gastric Neurostimulator Electrodes, Antrum, Open	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
46707	Repair Of Anorectal Fistula With Plug (Eg, Procine Small Intestine Submucosa [Sis])	K60.0-K60.5
47371	Laparoscopy, Surgical, Ablation Of 1 Or More Liver Tumor(S); Cryosurgical	C22.0-C22.9 C78.7
47381	Ablation, Open, 1 Or More Liver Tumor(S); Cryosurgical	C22.0-C22.9 C78.7
47383	Ablation, 1 Or More Liver Tumor(S), Percutaneous, Cryoablation	C22.0-C22.9 C78.7

Page **82** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

51715	Endoscopic Injection Of Implant Material Into The Submucosal Tissues Of The Urethra And/Or Bladder Neck	N39.3 R15.0-R15.9
53451	Bilateral periurethral transperineal adjustable balloon continence device	All
53452	Unilateral periurethral transperineal adjustable balloon continence device	All
53453	Removal of periurethral transperineal adjustable balloon continence device	All
53454	Fluid adjustment of Periurethral transperineal adjustable balloon continence device	All
55706	Biopsies, Prostate, Needle, Transperineal, Stereotactic Template Guided Saturation Sampling, Including Imaging Guidance.	All
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	All
57465	Computer-aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic quantification of the acetowhitening effect (List separately in addition to code for primary procedure)	All
58674	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency	All
61632	Destruction By Neurolytic Agent, Plantar Common Digital	All
61736	Laser interstitial thermal therapy of a simple single intracranial lesion	All
61737	Laser interstitial thermal therapy of multiple or complex intercranial lesions	All
61885	Insertion Or Replacement Of Cranial Neurostimulator Pluse Generator Or Receiver, Direct Or Inductive Coupling; With Connection To A Single Electrode Array	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9

Page **83** of **99**

61886	Incision And Subcutaneous Placement Of Cranial Neurostimulator Pulse Generator Or Receiver, Direct	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9
62263	Percutaneous Lysis Of Epidural Adhesions Using Solution Injection (Eg, Hypertonic Saline, Enzyme) Or Mechanical Means (Eg, Catheter) Including Radiologic Localization (Includes Contrast When Administered), Multiple Adhesiolysis Sessions; 2 Or More Days.	G96.8 G96.9
62264	Percutaneous Lysis Of Epidural Adhesions Using Solution Injection (Eg, Hypertonic Saline, Enzyme) Or Mechanical Means (Eg, Catheter) Including Radiologic Localization (Includes Contrast When Administered), Multiple Adhesiolysis Sessions; 1 Day.	G96.8 G96.9
62287	Percutaneous Decompression Procedure Of The Lumbar Spine	All
62380	Endoscopic Decompression Of Spinal Cord, Nerve Root(S), Including Laminotomy, Partial Facetectomy, Foraminotomy, Discectomy And/Or Excision Of Herniated Intervertebral Disc, I Interspace, Lumbar	All
64454	Injection(S), Anesthetic Agent(S) And/Or Steroid; Genicular Nerve Branches, Including Imaging Guidance, When Performed	All
64553	Percutaneous Implantation Of Neurostimulator Electrodes; Cranial Nerve	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9
64568	Incision For Implantation Of Cranial Nervestimulation Electrode Array And Pulse Generator	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9
64569	Incision For Implantation Of Cranial Nervestimulation Electrode Array And Pulse Generatorrevision Or Replacement	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9

Page **84** of **99**

64570	Incision For Implantation Of Cranial Nervestimulation Electrode Array And Pulse Generatorremoval Of The Elctrode Or Generator	F32.0-F33.9 G43.0-G44.89 H93.1-H93.19 H93.A1-H93.A9 M79.7 I50-I50.9 S06-S06.9X9
64590	Insertion Or Replacement Of Peripheral Or Gastri Neurostimulator Pulse Generator Or Receiver, Direct, Or Inductive Coupling	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
64595	Revision Or Removal Of Peripheral Or Gastric Neurostimulator Pulse Generator Or Receiver	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
64624	Destruction By Neurolytic Agent, Genicular Nerve Branches Including Imaging Guidance, When Performed	All
64625	Radiofrequency Ablation, Nerves Innervating The Sacroiliac Joint, With Image Guidance (Ie, Fluoroscopy Or Computed Tomography)	All
64628	Thermal destruction of intraosseous basivertebral nerve, first 2 vertebral bodies	All
64629	Thermal destruction of intraosseous basivertebral nerve, each additional vertebral body	All
64632	Destruction By Neurolytic Agent; Plantar Common Digital Nerve	G57.60-G57.62
64640	Destruction By Neurolytic Agent; Other Peripheral Nerve Or Branch	
64716	Neuroplasty And/Or Transposition; Cranial Nerve (Specify)	G43.001-G43.919 G44.0-G44.89
64722	Decompression, Unspecified Nerve (Specify)	G43.001-G43.919 G44.0-G44.89
64771	Transection Or Avulsion Of Other Cranial Nerve, Extradural	G43.001-G43.919 G44.0-G44.89
64772	Transection Or Avulsion Of Other Spinal Nerve, Extradural	G43.001-G43.919 G44.0-G44.89
64910	Nerve repair; with synthetic conduit or vein allograft (eg, nerve tube), each nerve	C61 N52.0-52.9
64911	Nerve repair; with autogenous vein graft (includes harvest of vein graft), each nerve	C61 N52.0-52.9
64912	Nerve repair; with nerve allograft, each nerve, first strand (cable)	C61 N52.0-52.9

Page **85** of **99**

64913	Nerve repair; with nerve allograft, each additional strand (List separately in addition to code for primary procedure)	C61 N52.0-52.9
67900	Repair Of Brow Ptosis (Supraciliary, Mid-Forehead Or Coronal Approach)	G43.001-G43.919 G44.0-G44.89
75571	Computed Tomography, Heart, Without Contrast Material, With Quantitative Evaluation Of Coronary Calcium	125.10-125.119 125.700-125.799 Z13.6
76120	Cineradiography/Videoradiograp, Except Where Specifically Included	All
76125	Cineradiography/Videoradiography To Complement Routine Examination (List Separately In Addition To Code For Primary Procedure)	All
76940	Ultrasound Guidance For, And Monitoring Of, Parenchymal Tissue Ablation	C22.0-C22.9 C78.7
77085	Dual-Energy X-Ray Absorptiometry (Dxa), Bone Density Study, 1 Or More Sites; Axial Skeleton (Eg, Hips, Pelvis, Spine), Including Vertebral Fracture Assessment	M80.08 M80.88 M81.0 M81.6 M81.8 Z13.820 Z13.828
77086	Vertebral Fracture Assessment Via Dual-Energy X-Ray Absorptiometry (Dxa)	M80.08 M80.88 M81.0 M81.6 M81.8 Z13.820 Z13.828
78195	Lymphatics And Lymph Node Imaging	C50.011-C50.929 C61 R92.0-R92.8 Z12.31-Z12.39
78800	Radiopharmaceuti-Cal Localization Of Tumor Or Distribution Of Radiopharmaceutical Agent(S); Limited Area	
78801	Radiopharmaceuti-Cal Localization Of Tumor Or Distribution Of Radiopharmaceutical Agent(S); Multiple Areas	R92.0-R92.8 Z12.31-Z12.39
78802	Radiopharmaceutical Localization Of Tumor Or Distribution Of Radiopharmaceutical Agent(S); Whole Body, Single Day Imaging	R92.0-R92.8 Z12.31-Z12.39
78804	Radiopharmaceutical Localization Of Tumor Or Distribution Of Radiopharmaceutical Agent(S); Whole Body, Requiring 2 Or More Days Imaging	R92.0-R92.8 Z12.31-Z12.39

Page **86** of **99**

78835	Radiopharmaceutical Quantification Measurement(S) Single Area (List Separately In Addition To Code For Primary Procedure)	All
81226	Cyp2D6 (Cytochrome P450, Family 2, Subfamily D, Polypeptide 6) (Eg, Drug Metabolism), Gene Analysis, Common Variants (Eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1Xn, *2Xn, *4Xn)	C50.011-C50.929 C79.81 D05.01-D05.99 D07.30-D07.39 Z13.71-Z13.79 Z85.3 Z80.3
81277	Cytogenomic Neoplasia Microarray Analysis	All
81313	Pca3/Klk3 (Prostate Specific Antigen 3 [Non- Protein Coding]/Kallikrein-Related Peptidase 3 [Prostate Specific Antigen]) Ratio (Eg, Prostate Cancer)	All
81400	Molecular Pathology Procedure, Level 1 (Eg, Identification Of Single Germline Variant [Eg, Snp] By Techniques Such As Restriction Enzyme Digestion Or Melt Curve Analysis) Includes The Following Test: Lct (Lactase-Phlorizin Hydrolase) (Eg, Lactose Intolerance), 13910 C>T Variant	All
81401	Apoe Common Varients	Z13.6 Z82.41 Z82.49

Page **87** of **99**

81403	Molecular Pathology Procedure Level 4	142.0
	(Eg Analysis Of Single Exon By Dna Sequence Analysis Analysis Of >10 Amplicons Using Multiplex Pcr In 2 Or More Independent Reactions Mutation Scanning Or Duplica Tion/Deletion Variants Of 2-5 Exons) Ang (Angiogen In Ribonuclease Rnase A Family 5) (Eg Amyotrophic	O36.0110-O36.0199 Z31.82
81406	Molecular Pathology Procedure, Level 7 (Eg, Analysis Of 11-25 Exons By Dna Sequence Analysis, Mutation Scanning Or Duplication/Deletion Variants Of 26-50 Exons, Cytogenomic Array Analysis For Neoplasia)	142.0
81407	Molecular Pathology Procedure, Level 8 (Eg, Analysis Of 26-50 Exons By Dna Sequence Analysis, Mutation Scanning Or Duplication/Deletion Variants Of >50 Exons, Sequence Analysis Of Multiple Genes On One Platform)	142.0
81415	Exome (Eg, Unexplained Constitutional Or Heritable Disorder Or Syndrome); Sequence Analysis	F70.0-F79
81416	Sequence Analysis, Each Comparator Exome (Eg, Parents, Siblings) (List Separately In Addition To Code For Primary Procedure)	F80.0-F89
81417	Re-Evaluation Of Previously Obtained Exome Sequence (Eg, Updated Knowledge Or Unrelated Condition/Syndrome)	Q00.0-Q99.9
81439	Inherited Cardiomyopathy (Eg, Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy) Genomic Sequence Analysis Panel, Must Include Sequencing Of At Least 5 Genes, Including Dsg2, Mybpc3, Myh7, Pkp2, And Ttn (New 01/01/2017)	142.0
81490	Autoimmune (Rheumatoid Arthritis) Analysis Of 12 B Iomarkers Using Immunoassays Utilizing Serum Progn Ostic Algorithm Reported As A Disease Activity Score	All

Page **88** of **99**

F	T	
81493	Coronary Artery Disease, mRNA, Gene Expression Profiling By Real-Time Rt-Pcr Of 23 Genes, Utilizing Whole Peripheral Blood, Algorithm Reported As A Risk Score.	I25.10 Z15.89 Z13.6
81500	Oncology (Ovarian), Biochemical Assays Of Two Proteins (Ca125 And He4), Utilizing Serum, With Menopausal Status, Algorithm Reported As A Risk Score - Is Specific To The Roma Test.	D27.0-D27.9 D39.10-D39.12 D49.511, D49.512, D49.159, D49.59 R19.01-R19.02
81503	Oncology (Ovarian), Biochemical Assays Of Five Proteins (Ca125, Apolipoprotein A1, Beta-2 Microglobulin, Transferrin And Prealbumin), Utilizing Serum, Algorithm Reported As A Risk Score - Is Specific To Ova1.	D27.0-D27.9 D39.10-D39.12 D49.511, D49.512, D49.159, D49.59 R19.01-R19.02
81504	Oncology (Tissue Of Origin), Microarray Gene Expression Profiling Of >2000 Genes, Utilizing Formalin- Fixed Paraffin Embedded Tissue, Algorithm Reported As Tissue Similarity Scores	C79.9 C80.0 C80.1
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported	All

Page **89** of **99**

	T	
81518	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy	All
81535	Oncology (Gynecologic), Live Tumor Cell Culture And Chemotherapeutic Response By Dapi Stand And Morphology, Predictive Algorithm Reported As A Drug Response Score; First Single Drug Or Drug Combination	C00.0-C96.9
81536	Each Additional Single Drug Or Drug Combination (List Separately In Addition To Code For Primary Procedure)	C00.0-C96.9
81538	Oncology (Lung), Mass Spectrometric 8-Protein Signature, Including Amyloid A, Utilizing Serum, Prognostic And Predictive Algorithm Reported As Good Versus Poor Overall Survival	C34.10-C34.92
81539	Oncology (High-Grade Prostate Cancer), Biochemical Assay Of Four Proteins (Total Psa, Free Psa, Intact Psa And Human Kallikrein 2 [Hk2]) Plus Patient Age, Digital Rectal Examination Status, And No History Of Positive Prostate Biopsy, Utilizing Plasma, Prognostic Algorithm Reported As A Probability Score	
81540	Oncology (Tumor Of Unknown Origin), mRNA, Gene Expression Profiling By Real-Time Rt-Pcr Of 92 Genes (87 Content And 5 Housekeeping) To Classify Tumor Into Main Cancer Type And Subtype, Utilizing Formalin-Fixed Paraffin- Embedded Tissue, Algorithm Reported As A Probability Of A Predicted Main Cancer Type And Subtype	C79.9 C80.0 C80.1
81560	Transplantation medicine, measurement of donor and third party-induced CD154+T-cytotoxic memory cells	All

Page **90** of **99**

04505	Condition (House T. L. 1) 5511	TO(20 TO(200 740 24
81595	Cardiology (Heart Transplant), mRNA, Gene Expression Profiling By Real-Time Quantitative Pcr Of 20 Genes (11 Content And 9 Housekeeping), Utilizing Subfraction Of Peripheral Blood,	
82107	Alpha-Fetoprotein (Afp); Afp-L3 Fraction Isoformand Total Afp (Including Ratio)	All
82172	Apolipoprotein	All
82239	Bile acids; total	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
82272	Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
82274	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
82397	Chemiluminescent	Z13.6 Z82.41 Z82.49
82523	Collagen Cross-Links, Any Method	M81.0-M81.8 Z13.820 Z82.62
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
82610	Cystatin C	All
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed	Z13.6 Z82.41 Z82.49
82656	Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
82664	Electrophoretic technique, not elsewhere specified	All
82710	Fat or lipids, feces; quantitative	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89

Page **91** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

		I
82715	Fat differential, feces, quantitative	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8
		K63.9 K90.89
82725	fatty acids, nonesterified	A04.8, A04.9
	,	K58.0, K58.1, K58.2, K58.8,
		K58.9 K59.8
		K63.9
		K90.89
83006	Growth Stimulation Expressed Gene 2	150.1-150.9
02520	(St2 Interleukin 1 Receptor Like-1)	1010 1010 502 00 502 01
83520	(Immunoassay For Analyte Other Than	A04.8, A04.9 F03.90, F03.91
	Infectious Agent Antibody Or	G30.0-G30.9
	Infectious Agent Antigen;	G31.1 K58.0, K58.1, K58.2, K58.8,
	Quantitative; Not Otherwise Specified)	K58.9 K59.8 K63.9 K90.89 R41.0
	Specified)	R41.81 Z13.858
83630	Lactoferrin, fecal; qualitative	A04.8, A04.9
	, , ,	K58.0, K58.1, K58.2, K58.8,
		K58.9 K59.8
		K63.9 K90.89
83695	Lipoprotein (A)	Z13.6
		Z82.41 Z82.49
83698	Lipoprotein-Associated	Z13.6 Z82.41 Z82.49
02724	Phospholipase A2 (Lp- Pla2)	All
83721	Lipoprotein, direct measurement; LDL cholesterol	All
83722	Lipoprotein, Direct Measurement;	All
03722	Small Dense Ldl Cholesterol	Att
83880	Natriuretic Peptide	All
83937	Osteocalcin (Bone G1A Protein)	E21.0
	(M81.0-M81.8 M88
		N25.0 Z13.820 Z82.62
83986	pH; body fluid, not otherwise	A04.8, A04.9
	specified	K58.0, K58.1, K58.2, K58.8,
00007		
84080	Phosphatase, Alkaline; Isoenzymes	
84181	Western Riot With Interpretation	
		All
84311	•	A04.8. A04.9
		
		K58.9 K59.8
		K63.9 K90.89
83987 84080 84181 84311		K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89 All E21.0 M81.0-M81.8 M88 N25.0 Z13.820 Z82.62 All A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8

Page **92** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

85384	Fibrinogen; Activity	Z13.6 Z82.41 Z82.49
85385	Fibrinogen; antigen	All
86141	C-Reactive Protein; High Sensitivity (Hscrp)	Z13.6 Z82.41 Z82.49
86304	Immunoassay For Tumor Antigen, Quantitative; Ca-125)	Z12.73
86305	Human Epididymis Protein 4 (He4).	All
86352	Cellular Function Assay Involving Stimulation (Eg, Mitogen Or Antigen) And Detection Of Biomarker (Eg, Atp).	T86.10-T86.819 T86.890-T86.899 Z94.0-Z94.4 Z94.83-Z94.89 Z94.9
87045	Culture, bacterial; stool, aerobic, with isolation and preliminary examination (eg, KIA, LIA), Salmonella and Shigella species	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87046	Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87075	Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87102	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood)	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87177	Ova and parasites, direct smears, concentration and identification	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87209	Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87328	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme- linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; cryptosporidium	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89

Page **93** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

87329	Infectious agent antigen detection by	A04.8, A04.9
	immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; giardia	K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87336	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Entamoeba histolytica dispar group	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID- 19])	All
88375	Optical Endomicroscopic Image(S) Interpretation And Report Real- Time Or Referred Each Endoscopic Session	K22.70-K22.719 Z13.810 Z13.811 Z13.83
89160	Meat fibers, feces	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
89161	fibers, feces	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89
89240	Unlisted miscellaneous pathology test	A04.8, A04.9 K58.0, K58.1, K58.2, K58.8, K58.9 K59.8 K63.9 K90.89

Page **94** of **99**

90626	Tick-borne encephalitis virus	All
	vaccine, inactivated; 0.25 mL	
	dosage, for intramuscular use	
90627	Tick-borne encephalitis virus	All
	vaccine, inactivated; 0.5 mL	
	dosage, for intramuscular use	
90671	Pneumococcal conjugate vaccine,	All
	15 valent (PCV15), for	
	intramuscular use	
90758	Zaire ebolavirus vaccine, live, for	All
00750	intramuscular use	
90759	Hepatitis B vaccine (HepB), 3-	All
	antigen (S, Pre-S1, Pre-S2), 10 mcg	
	dosage, 3 dose schedule, for	
00077	intramuscular use	F00 0
90876	Application Of A Modality To One Or	F98.0
	More Areas; Electrical Stimulation	F98.1 N39.3 N39.041-N39.498 R15.9
92229	(Unattended)	
92229	Imaging of retina for detection or	All
	monitoring of disease; point-of-	
	care automated analysis and report, unilateral or bilateral	
92549	Computerized Dynamic	All
72347	Posturography Sensory Organization	Att
	Test.	
93050	Arterial Pressure Waveform Analysis	All
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	For Assessment Of Central Arterial	
	Pressures, Includes Obtaining	
	Waveform(S), Digitization And	
	Application Of Nonlinear	
	Mathematical Transformations To	
	Determine Central Arterial Pressures	
	And Augmentation Index, With	
	Interpretation And Report, Upper	
	Extremity Artery, Non-Invasive	
93264	Remote Monitoring Of A Wireless	All
	Pulmonary Artery Pressure Sensor For	
	Up To 30 Days, Including At Least	
	Weekly Downloads Of Pulmonary	
	Artery Pressure Recordings,	
	Interpretation(S), Trend Analysis, And	
	Report(S) By A Physician Or Other	
02257	Qualified Health Care Professional	All
93356	Myocardial Strain Imaging	All
93701	Bioimpedance-Derived Physiologic	150.1-150.9
	Cardiovascular Analysis	

Page **95** of **99**

93895	Quantitative Carotid Intima Media	Z13.6
75075	Thickness And Carotid Atheroma	213.0
	Evaluation, Bilateral	
95012	Nitric Oxide Expired Gas	All
75012	Determination	Att
95812	Electroencephalogram (EEG)	F90.0-F90.9
75012	extended monitoring; 41-60 minutes	1 70.0-1 70.7
95813	Electroencephalogram (EEG)	F90.0-F90.9
75015	extended monitoring; 61-119	1,0.01,0.7
	minutes	
95816	Electroencephalogram (EEG); including	F90.0-F90.9
	recording awake and drowsy	
95819	Electroencephalogram (EEG);	F90.0-F90.9
	including recording awake and	. , , , , , , , , , , , , , , , , , , ,
	asleep	
95905	Motor And/Or Sensory Nerve	All
	Conduction, Using Preconfigured	
	Electrode Array(S), Amplitude And	
	Latency/Velocity Study, Each Limb,	
	Includes F-Wave Study When	
	Performed, With Interpretation And	
	Report.	
95921	Testing Of Autonomic Nervous	ANY OF A LARGE NUMBER OF
	System Function; Cardiovagal	DIAGNOSIS CODES MIGHT
	Innervation (Parasympathetic	APPLY TO THIS POLICY, THE
	Function), Including 2 Or More Of	FOLLOWING IS NOT A
	The Following: Heart Rate	COMPLETE LIST:
	Response To Deep Breathing With	E10.40-E10.49 E85.1-E85.8
	Recorded R-R Interval, Valsalva	G61.0-G61.9 G90.01-G90.9
	Ratio, And 30:15 Ratio	M32.0-M32.9 M35.00-M35.09 R55
95922	Testing Of Autonomic Nervous System	ANY OF A LARGE NUMBER OF
	Function; Vasomotor Adrenergic	DIAGNOSIS CODES MIGHT APPLY
	Innervation (Sympathetic Adrenergic	TO THIS POLICY, THE
	Function), Including Beat-To-Beat	FOLLOWING IS NOT A COMPLETE
	Blood Pressure And R-R Interval	LIST:
	Changes During Valsalva Maneuver And	
	At Least 5 Minutes Of Passive Tilt	G61.0-G61.9 G90.01-G90.9
95923	Tosting Of Autonomic Namous System	M32.0-M32.9 M35.00-M35.09 R55 ANY OF A LARGE NUMBER OF
73743	Testing Of Autonomic Nervous System	DIAGNOSIS CODES MIGHT APPLY
	Function; Sudomotor, Including 1 Or	TO THIS POLICY, THE
	More of The Following: Quantitative Sudomotor Axon Reflex Test (Qsart),	FOLLOWING IS NOT A COMPLETE
	Silastic Sweat Imprint,	LIST:
	Thermoregulatory Sweat Test, And	E10.40-E10.49 E85.1-E85.89
	Changes In Sympathetic Skin Potential	G61.0-G61.9 G90.01-G90.9
	Changes in Sympacietic Skiii i Otelitiat	M32.0-M32.9 M35.00-M35.09 R55
		7102.0 1102.7 1100.00 1100.07 1100

Page **96** of **99**

95924	Testing Of Autonomic Nervous System Function; Combined Parasympathetic And Sympathetic Adrenergic Function Testing With At Least 5 Minutes Of Passive Tilt	ANY OF A LARGE NUMBER OF DIAGNOSIS CODES MIGHT APPLY TO THIS POLICY, THE FOLLOWING IS NOT A COMPLETE LIST: E10.40-E10.49 E85.1-E85.89 G61.0-G61.9 G90.01-G90.9 M32.0-M32.9 M35.00-M35.09 R55
95957	Digital Analysis Of Electroencephalogram (Eeg) (Eg, For Epileptic Spike Analysis)	F90.0-F90.9
95976	Electronic Analysis Of Implanted Neurostimulator Pulse Generator/Transmitter (Eg, Contact Group[S], Interleaving, Amplitude, Pulse Width, Frequency [Hz], On/Off Cycling, Burst, Magnet Mode, Dose Lockout, Patient Selectable Parameters, Responsive Neurostimulation, Detection Algorithms, Closed Loop Parameters, And Passive Parameters) By Physician Or Other Qualified Health Care Professional; With Simple Cranial Nerve Neurostimulator Pulse Generator/Transmitter Programming By Physician Or Other Qualified Health Care Professional	All

Page **97** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

95977	Electronic Analysis Of Implanted Neurostimulator Pulse Generator/Transmitter (Eg, Contact Group[S], Interleaving, Amplitude, Pulse Width, Frequency [Hz], On/Off Cycling, Burst, Magnet Mode, Dose Lockout, Patient Selectable Parameters, Responsive Neurostimulation, Detection Algorithms, Closed Loop Parameters, And Passive Parameters) By Physician Or Other Qualified Health Care Professional; With Complex Cranial Nerve Neurostimulator Pulse Generator/Transmitter Programming By Physician Or Other Qualified Health Care Professional Electronic Analysis Of Implanted Neurostimulator Pulse Generator	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
	System (Eg, Rate, Pulse Amplitude And Duration, Configuration Of Wave Form, Battery Status, Electrode Selectability, Output Modulation, Cycling, Impedance And Patient Measurements), Gastric Neurostimulator Pulse Generator/Transmitter; Intraoperative, With Programming	E13.43 K31.09
95981	Subsequent, Without Reprogramming	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
95982	Subsequent, With Reprogramming	E08.43 E09.43 E10.43 E11.43 E13.43 K31.89
96904	Whole Body Integumentary Photography, Formonitoring Of High Risk Patients With Dysplasticnevus Syndrome Or A History Of Dysplastic Nevi, Orpatients With A Personal Or Familial History Of Melanoma	C43.0-C43.9 D22.0-D22.9 D23.0-D23.9
97014	Application of a modality to 1 or more areas; electrical stimulation (unattended)	F98.0 F98.1 N39.3 N39.41 -N39.498 R15.9

Page **98** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022

97032	Application Of A Modality To One Or More Areas; Electrical Stimulation (Manual), Each 15 Minutes	E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 F98.0 F98.1 I83.001-I83.029 I83.201-I83.229 L00-L08.9 L89.00-L89.95 L97.10- L97.929 L98.41-L98.499 L99 N39.3 N39.41-N39.498 R15.9
97033	Ionotphoresis	All
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes	All
97610	Low Frequency, Non-Contact, Nonthermal Ultrasound, Including Topical Application(S), When Performed, Wound Assessment, And Instruction(S) For Ongoing Care, Per Day.	E08.621 E08.622 E09.621 E09.622 E10.621 E10.622 E11.621 E11.622 E13.621 E13.622 I83.001-I83.029 I83.201-I83.229 L00-L08.9 L89.00- L89.95 L98.411-L98.499 L97.10-L97.929 L98.411-L98.499
98922	Testing Of Autonomic Nervous System Function; Vasomotor Adrenergic Innervation (Sympathetic Adrenergic Function), Including Beat-To-Beat Blood Pressure And R-R Interval Changes During Valsalva Maneuver And At Least 5 Minutes Of Passive Tilt	ANY OF A LARGE NUMBER OF DIAGNOSIS CODES MIGHT APPLY TO THIS POLICY, THE FOLLOWING IS NOT A COMPLETE LIST: E10.40-E10.49 E85.1-E85.8 G61.0-G61.9 G90.01-G90.9 M32.0-M32.9 M35.00-M35.09 R55

Page **99** of **99** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2022